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ABSTRACT
Breakthroughs in tissue engineering are moving at a rapid rate, especially
in regenerative bone biofabrication. Technology growth in the field of additive
manufacturing (AM) such as 3D bioprinting which provides the ability to create a
biocompatible 3D construct on which a cell source could be seeded is an
encouraging substitute to autologous grafts.
This present research aims to biofabricate a construct for bone tissue
engineering using AM technology. The biocompatible material was chosen
corresponding to the skeletons extracellular matrix (ECM) composition, which
demonstrates an inorganic and organic development phase: Poly (lactic-glycolic
acid) was chosen as the polymeric matrix of the compound, due to its bioactivity,
biocompatibility, and ability to regulate biodegradability to support cell and bone
function; graphene-nanoparticle were chosen for mechanical and organic
reinforcement to support the mineral phase of the ECM.
A commercial 3D bioprinter called the Aether 1 was used. The printer is a
pneumatic based printer, which allows printing from hydrogels to thermo
polymers. The bioprinter is located in the Regenerative Medicine Lab in the
Large Animal Clinical Sciences.
The first part of our study was to show the relationship of mesenchymal
stem cells and graphene-nanoparticles. This was to evaluate the ECM layout on
the graphene for biocompatibility and establish markers for supporting
osteogenesis. Second part of the research dealt with finding a safe solvent to
melt the different molar ratios of PLGA and the blending in of graphenenanoparticles for low thermodynamic and low-pressure printing. This work dealt
with the characterization, constating in the evaluation of different extrusion
speeds, pressure values and nozzle diameters to construct a 3D print for testing
the biocompatibility and cellular behavior. The final study was to utilize the 3D
constructs in a long bone segmental defect model to characterize its in vivo
capabilities.
v

This work proved that the biofabrication of the PLGA+graphene
nanoparticle blend could be achieved and repeatable with 3D bioprinting,
supports cellular behavior for regeneration and provided results in the long bone
defect study.
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3D PRINTING: INSIGHT INTO THE MATRIX ARCHITECTURE AND
CONTACT GUIDANCE OF CELL BEHAVIOR
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Abstract
Nearly thirty years ago a technology was brought to light that had no
understanding how it would change science, medicine and manufacturing. The
production of 3D models used in many avenues has grown greatly over the years. The
reviewed literature works has gone back many years, but this review will cover a period
of the last 10-15 years when printing manufactures entered, and 3D printing grew at a
pace from only structure formations to new construct biocompatible materials with stem
cells and supporting components. This chapter outlines the application of 3D printing in
tissue and organ regeneration, productions of new materials for fabrication and
biofabrication and its effects on economics for this technology. Stereolithography is
what Hull, 3D printing inventor, called his first 3D printing automation. He secured a
patent for his invention and established a 3D System to make and commercialize 3D
printers (Prince, 2014).
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Introduction
To heal or replace, which treatment for tissue damage or organ failure? This is
where regenerative medicine comes into play with a goal to engineer tissues for
transplantation and replacement. This is primarily due to organ shortage and the tool to
aid in this task of bio-manufacturing is three-dimensional printing or bioprinting. The
goal of 3D printing is to meet the need and match patient specific resolution. The
approach of 3D bioprinting is a growing application for multiple tissue engineering
challenges with tissue regeneration being the end goal. The body of any animal is
profoundly complex with a multiplex of tissue types. Organs of these complex systems
are formed by extremely specialized cells with complex functions. Three-dimensional
framework of multicellular tissues defines different roles, providing organ structural
integrity but also indicate functional organ perimeters and depict the microenvironment
niche (Mecham, 2012). With an avenue of cells, bioactive/growth molecules or factors
and a scaffold, it is imperative to consolidate the foundation of cellular and molecular
biology with material science to form the cocktail to engineer this needed 3D
environment. Controlling and understanding the cellular surroundings is a vital step for
engineering a material for cellular function (Jiang, 2003). No matter the application or
the need, the approach is to achieve cell survival with an objective for the restoration
and function of a tissue. Regardless of the strategic approach the ultimate host
response to the implanted construct will direct the accomplishment or collapse of 3D
bioprinting.
Many primary cell lineages are complex to isolate and culture in vitro with a
narrow lifespan (Dimri, 1995). Mesenchymal stem cells (MSCs) which can be isolated
from any adult somatic tissue have the potential to self-renew and differentiate leading
to an unlimited cell source for tissue regeneration when they are combined with a welldeveloped 3D bioprinted/-biofabricated construct. The stem cell niche is a convoluted
3D environment which impacts cell fate. Within the stem cell system, the exchange of
oxygen and growth factors, cell-cell association as well as cell-matrix adherence are
required for regulation (Discher, 2009). Therefore, the accurate biofabrication of this
niche-like environment is a crucial matter in stem cell biology and regenerative

4

medicine. The construction of stem cell niches and tissue constructs is very challenging
from a technical point of view because of their complexity.
By this measure there is a demand to cultivate a genuine matrix substitute
to replace traditional 3D scaffolds. Bioprinting is an additive manufacturing (AM), where
the scaffold design for fabrication layout starts with computer-aid design (CAD)
software, then data is transferred into a code that directs the 3D printer to print in a
layer-by-layer composition (Figure 1.1). This chapter is subdivided to include the
details of the most common 3D printing and bioprinting technologies. Attention has
been placed in extrusion-based printing/bioprinting automation. In the last section, it
details the importance of the biofabrication in mimicking of extracellular matrix to
improve cell survival for implantation.
3D Bioprinting Building Blocks
According to the National Institute of Health, tissue engineering is a strategy that
uses a combination of cells, specifically designed and engineered materials, and
suitable biochemical and physicochemical factors to restore, maintain, improve, or
replace different types of biological tissues. Regenerative medicine is a broad filed of
tissue engineering. Tissue engineering using stem cells requires the appropriate niche
for proper proliferation and differentiation. Technically, engineering the stem cell niche is
considered as the most challenging aspect of tissue engineering. 3D printing provides
the three-dimensional environment for the cells and helps them to maintain their cell-cell
contact and thus, their function. In conventional 2D cultures, primary cells rapidly lose
their function, in large part due to distressed cell-cell contacts, further emphasizing the
importance of 3D printing. As a result, 3D printing of materials provides a structure for
the function of endogenous and exogenous cells. The 3D scaffold alone i.e., an
acellular scaffold has the potential to provide a structure for endogenous cells to
function appropriately. It can also be combined with exogenous cell populations to
design highly sophisticated constructs that mimic the natural tissue and hence, can be
adapted for use of living material. The approach of 3D bioprinting of either material
alone or of constructs consisting of materials and living cells has the potential to
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reconstruct tissue from various regions of the body. This technology can also potentially
be applied to bone, skin, cartilage and muscle tissue.
In 3D printing, several technical issues have to be considered before any cellular
component can be included. These include the choice of printing technology, choice of
the biomatrix, printing parameters, and subsequently, considerations of the interaction
between the materials and cells. The scaffold is designed in a CAD program, then
coded to the 3D printer for a structure formation in a layer-by-layer format. The 3D
bioprinter is a multi-tool printer allowing for multiple fabrication methods and printing
cells and biological materials in programed patterns and gradients. Microextrusion is the
common choice of printing and is essentially the same as that used in thermal inkjet
printing, which can attain a spatial resolution of hundreds of micrometers. Microjet
extruder bioprinting is the process in which designed droplets are deposited onto the
scaffolds in a layer-by layer preprogrammed design. The choice of the materials that
can be printed is endless, and in biomedicine, the choice of the material is highly
dependent on the applications and the cells that will be either printed or manually added
onto the printed scaffold, or the nature of the cells that the implanted scaffold will be
exposed to in the body (Tappa, 2018).
Additive Manufacturing – Making Three Dimensional Scaffolds
The additive process is the formation of a 3D printed scaffold or object. It is
developed by the blending of materials. The material is placed through a technology
which creates successive layers of blended materials and a physical object is
assembled. The common desktop printer, the inkjet, which was brought to use in the
seventies was attached to a computer to receive commands. This constituted the whole
building platform for the 3D printer. The inkjet required a data file and a computer
connection controller to have complete operation. A modern 3D printer also requires a
data file based on the physical objects’ 3D model, and post-modeling code after the
model is printed. Metal alloy, synthetic polymers and now biological tissues must be
considered because the choice of the material alters the processing method and hence
is needed to achieve the needed design. The American Society for Testing and
Materials produced a white paper in 2017 by Picariello that categorized the process of
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additive manufacturing into seven groups based on the manufacturing process. These
groups include material extrusion, energy direct deposition, sheet lamination, powder
bed fusion, binder jetting, material jetting and vat photo polymerization (Picariello,
2017).
Computer-aided Design, G-code and Computer – aided Tissue Engineering
CAD software is where 3D printing begins for the manufacturing process. The
operator designs a digital model of the desired architecture in the levels of macro, micro
and nano scales for the overall shape of the needed scaffold. In the fabrication or
biofabrication the microarchitecture of the overall design allows for the complex
structures of anatomical features; the micro design mirrors the tissue layout including
pore size and interconnectivity and spatial distribution; and the nano design looks at the
constructs’ surface properties for cell adhesion, proliferation, differentiation and
biomolecular attachment. CAD has allowed for complex biofabrication of 3D scaffolds
to meet specific patient needs. CAD software has the coding for integration of imaging
techniques such as computer tomography and magnetic resonance imaging, thereby,
translating the CT and the MRI images directly into the printer. The ability of utilizing
this technology has allowed for more advanced prototype scaffold designing,
manipulation and biofabrication of macro to nanoarchitecture. Once the scaffold is
developed in the CAD software, the CAD file is converted to a standard industry format
as a stereolithography file. The stereolithography file is known as the STL file,
developed by Hull, is based on a geometrical format using triangular shapes (Kwok et
al., 2017). The STL file is then split into layers in the layer-by-layer design by a process
known as slicing. The slicing software effectively translates the 3D scaffold into a
control language known as a G-code. A G-code is a language written in a numerical
control program that sends a code or instructions to the printer. A G-code is specific to
the printer or the bioprinter and the additive manufacturing method which is being
utilized (Kwok et al., 2017). The G-code provides the language that the 3D printer can
translate and use to print.
The architecture of computer-aided tissue engineering (CATE) allows for
advancement of biomaterials and biomedical device to be designed and biofabricated
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into a complex 3D construct and be patient tissue specific. The careful layout must
review all levels of the macro, micro and nano components. The complexity of the
overall macroarchitecture shape being the anatomical structure must be mimicked, the
microarchitecture must relate closely to the tissue matrix being porosity, spatial
distribution and interconnectivity. The nanoarchitecture will build the strong attraction
for cell adhesion, proliferation, and differentiation for a mature development. Using
CATE with micro-CT and MRI data allows for the layout for a rapid prototyping of the
construct’s macro and micro biofabrication quality (Winder, 2005). The support of
CATE leads the way to a rapid prototyping, called solid free form fabrication (SFF),
allowing the design of the construct’s complex macro and microarchitecture for detailed
engineering.

Solid Freeform (SFF) Biofabrication
The process of forming a 3D device is done in a layer-by-layer method with SFF
biofabrication. A computer model using data from a medical image such as micro-CT
and radiology views is developed for the proper geometry. Next, the 2D computer
model images are software generated forming a 3D rendering. A layer-by-layer model
for biofabrication has the ability to input nanoarchitecture modification on any surface in
post process if needed. The use of SFF has advantages to print complex designs,
allowing for highly convoluted structure overhangs or volume infills. The ability of
processing multiples of parameters and layouts before processing, specifically with
control of pore morphology and varying porosities at different levels of biofabrication is a
very important manufacturing process. This becomes significant when dealing with the
complexity of mammal anatomy. A modified method of 3D printing, stereolithography
(SLA), fused deposition modeling (FDM), and bioplotting are a few SFF technologies
briefly described below.

Structural Parameter - Limitations and Accuracy
How closely does the 3D fabricated scaffold compare to the CAD file to give a
sound call for accuracy? Many software features and the location of the XY resolution
are some of the factors involved in maintaining the dimensional accuracy.
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Structural resolution dictates a printing system’s ability to accurately build the
detailed features of the scaffold. In the fabrication process, repeatability of
measurement is processed by the printer and not the CAD design. An important
variable in 3D printing is spatial resolution. Tissue extracellular matrix and construction
varies in the hundreds of microns making this variable one of the most challenging to
control in biofabrication. Within most body tissues, cells need to maintain homeostasis
staying generally no more than 100 – 200 μm away from capillaries (Lovett et al.,2009).
Therefore, bioengineered devices and scaffolds are diffusion limited in size due to lack
of vasculature. As a result, culturing cells at physiological densities without ample
vascularization can lead to necrosis (Miller et al., 2012).

3D Printing
Massachusetts Institute of Technology has taken the technology to develop a
modified version of three-dimensional printing (3DP) (Wu, 1996). The process design
for this method was to first build a 3D object with particles of a layer of thin loose
powder, next the printhead deposits a liquid binder creating a pattern from the bound
powder particles. This was a layer-by-layer design system. When complete, the
designed components are removed from the print bed of powder and loose powder is
detached. This method of printing utilized the loose powder to support overhand
structural features and channels within the structure. As a result, the 3DP was
composed of the powder and the binder. Organic solvent such as Diethylene Glycol
can be utilized as binders while most powders were composed of synthetic polymers
such as poly (ε-caprolactone), polylactide–coglycolide or poly (L- lactic acid) (Wu,
1996). Other inkjet systems used natural polymer powders such as starch, gelatin mix
and dextran with water as the binding agent (Seitz et al., 2005). Indirect method of 3DP
utilizes a printed mold design which is later cast with a porogen material and polymer
mix. Calcium sulfate hemihydrate plaster powder with a water-based binder, is typically
cast as the mold later mixed to form a biodegradable polymer slurry which is dissolved
in polylactide–coglycolide in chloroform mixed with NaCl as the solvent (Lee, 2008).
The abundant range of natural and synthetic material powder forms and the
ability to print at room temperature is a key to 3DP. Controlling all levels of overhang
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extensions, design with microstructure manipulation and set full adjustments to internal
architecture gives many advantages. The 3DP disadvantages include the limited
organic solvents that can be used as binders due to the damage caused to the
printhead and, secondly the powders clog small pores and curved channels within the
construct.

Stereolithography - Photopolymerization
The design of this printer is to utilize a controlled irradiated laser or light to
solidify the geometrically created 2D pattern through photopolymerization in the resin
reservoir. This method was used by Hull when 3D printing came to light (Hull, 1986).
Overall, the primary improvement of stereolithography-based bioprinting is the ability to
simply fabricate multiplex scaffold designs with high resolution and rapidly print
constructs without needed support material (Murphey, S.V. and Atala, A., 2014; Park et
al., 2017). SLA materials used are limited because they should be photocrosslinkable.
Hence, poly (propylene fumarate) (Lee, et al., 2007) and PEG dimethacrylate
formulations are commonly used. SLA is moving towards using biodegradable materials
by synthesizing different polymers like macromers. SLA has a higher resolution but a
longer print time than Fused Filament. The future of cell work with SLA includes
encapsulation of cells during polymerization in processed hydrogels. The method still
has many limitations such as cytotoxicity of the initiator and exposure to UV light, but
teams are reviewing the needed changes including the use of hydrogels, which can
prove very helpful in regenerative medicine.

Fused Deposition or Fused Filament Printing
This fabrication method works by building consecutive layers of a polymer at high
temperatures, allowing the adjacent layers to cool and form a bond before the next
deposited layer is extracted. This fabrication method has limited resolution and
accuracy due to the motors and print time. Fused fabrication has the ability to be easily
customized for scaffold designs and can be hollow or infill to save material cost.
Depending on the scaffold and the CAD design, the structures may need support
anchors which could inhibit the fused deposition process.
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Inkjet Bioprinting
Inkjet bioprinting is based on the usage of cell-laden bioink droplets which are
generated and deposited to established pre-defined scaffold regions (Figure 1.2). An
advantage to droplet bioprinting is the ability to allow for concentration gradients of cells,
materials or growth factors throughout the 3D scaffold by altering droplet densities or
proportions (Nakamura, 2005). Current research is utilizing droplet bioprinting for
“scaffold-free” print design which consists of depositing layers of concentrations of cells
in a sacrificial scaffold mold.

3D Plotting and Bioplotting
This technology is an all-purpose rapid prototyping printer that is capable of
transforming an assortment of biomaterials using biofabrication from CATE. Being very
similar to FDM, a nozzle is used to extrude the melted material into the form of filament
which solidifies on the cooled print bed. A well-built bioplotter system can fabricate or
Biofabricate scaffolds using an extensive spectrum of materials, ranging from hydrogels,
polymers and hard ceramics and metals. In the biofabrication process, 3D bioplotting
has the capability for the design to incorporate multiple cell types into the structure
during the printing phase of the complete process.

Bioink Selection for Tissue Scaffold
The extracellular matrix is the backbone to tissue regeneration for cell
proliferation, adhesion and differentiation. The ECM is generated either by the cells that
are implanted exogenously or by the endogenous cells when they are exposed to 3D
printed scaffolds (Newby et al., 2020). Hence, the choice of the “bioinks” for a specific
printer is an important factor in tissue engineering. Bioinks constitutes the biomaterial
(s) that is extruded by a printing nozzle or needle that generates a biofabricated matrix
for cells while they produce the needed extracellular matrix for tissue regeneration.
Alternatively, the ECM can be generated by blending natural or synthetic materials in
vitro and used as a bioink.

Bioinks are characterized as structural, functional or

supportive (Chia, 2015). The mechanical means of the developed bioink must target
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the needed cell forces allowing for signaling pathways leading to cell survival and tissue
development (Dussoyer et al., 2000). The development of these materials needs to be
studied in a step-by-step process for purification, material modification and the most
challenging sterilization to be utilized in regenerative medicine applications.

Acellular and Cellular Biofabrication
Acellular scaffolds are those that typically mimic the biochemical and mechanical
properties of the tissue ECM Scaffolds provide the environment for cellular attachment
to stimulate tissue regenerative response. Acellular bioprinting allows for a greater
extent for material selection for biofabrication. Acellular scaffolds must be bioresorbable
and biocompatible and should demonstrate the potential to generate signals for
biochemical, biomechanical and biophysical cues for cell migration and differentiation
(Hutmacher, 2000). Additionally, cellular scaffolds without any cellular component can
be merely implanted into patients for structural and functional support in the
regenerative process.
The biofabrication of a 3D cellular construct implements living cells in the design
procedure. Assorted emulsions have been developed to generate a 3D matrix of living
tissue with each iteration having different strengths and limitations. Bioinks
incorporating cells have additional requirements, and thus, pose significant challenges.
The printing process must preserve cell integrity and viability during resuspension and
passage through the bioprinter nozzle and preparation of an environmental niche for cell
growth and function within the printed biofabricated scaffold [Wust et al., 2011]. The
deposition of the bioink depends on the printing mechanism. The representative
techniques of cellular bioprinting can be categorized into three methods: extrusionbased (pneumatic-, mechanical-, and solenoid-based), stereolithography and dropletbased (Skardal, 2015).

Tissue Engineering
Different designs of scaffolds and printing as mentioned earlier greatly depend on
the method of additive manufacturing process. The ability to control degradation and
resorption rates to resemble normal tissue with favorable mechanical properties and
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exceptional biocompatibility both in vitro and in vivo are required in engineering
experimental steps (Cancedda, 2007). The biofabrication design of the scaffold should
provide a three-dimensional support for tissue regeneration. This process should
support cell proliferation leading to differentiation while promoting growth with
surrounding vessels, resulting in an iteration with an end goal to replace the sustaining
loads and functions of the flawed tissue. The biofabricated construct should acquire a
repository of biochemical and biophysical cues to promote precise response at the
cellular level for tissue development.

Cells for Biofabrication
The most abounding cell source in the body to support bioengineering is the
MSCs. MSCs may be isolated from adipose tissue and bone marrow and have
capability for self-renewal and to differentiate into multiple cell linages in proper
conditions in vitro and in vivo (Lee et.al., 2001). Our focus in the use of cells in
biofabrication centers on the use of adipose - and bone marrow - derived MSCs. MSCs
can also be classified as autologous and allogenic. Autologous cells are transplanted
from yourself, while allogenic cells are transplanted from a donor. In human medicine,
autologous stem cells have been used in medical treatment of injury and disease
(Tobiat, 2011), while a number of clinical trials are ongoing to promote the use of
allogenic cells (www.clinicaltrial.gov) Combination of the cell’s ability for self-renewal
and capacity to differentiate into chondrogenic, adipogenic, osteogenic and angiogenic
lineages and a well-designed architecture construct plays an important role in the
various stages for regeneration of tissue (Cherubino et al., 2011).
Various cell types have been printed using a 3D bioprinter. One of the
impediments of engineering any scaffold is the ineffectiveness to biomimic the
extracellular matrix of healthy tissue in the body when multiple cell types are integrated
(Xu et al., 2013). With the ability to design a structured pattern providing an optimal
environment for cells can prove to be very advantageous in regenerative medicine.
Printers are adjustable, multitask, easily reprogrammed with a new CAD template and
are provided with interchangeable stainless-steel blunt tip needles for injection to
accommodate different biomaterials and/or multiple cell types. Recent momentum has
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been placed on printing scaffolds which can serve as biomimetic components that can
orchestrate tissue regeneration, provide tissue support, direct tissue regeneration and
integration within a host tissue. As a result, some of the basic material elements that are
considered during the printing process include percent porosity with ranging
dimensions, internal geometric and projection modeling, biodegradation dynamics,
mechanical properties, and cell biocompatibility. As a result, a lot of research and
design is required to find an optimal material for a particular application (Guvendiren,
2016).
With the recent advances in cell-based therapies, 3D printing is becoming an
increasingly common technique to generate scaffolds and medical devices for tissue
engineering applications. In the last decade, extensive research has been carried out
towards developing biomaterials that are capable of mimicking the physiological and
biological microenvironment of mesenchymal stem cells along with physicochemical
properties that will control the cell behavior and fate. Controlling cell behavior is one of
the most important topics in regenerative medicine and is of particular interest to
researchers by which the lessons can be transferred to the clinic with improved
outcomes. Some of the factors that need special consideration in 3D printing of
materials conducive for controlled cell behavior are highlighted below.

Extracellular Matrix
Remembering that the role the ECM plays is a critical position in providing
structural support through ligands such as type I collagen and fibronectin which interact
with MSCs in promoting remodeling (Salmasi et al., 2015). During the tissue repair
process the interaction between MSCs, native tissue cells, biofabricated construct and
the ECM trigger cell signaling, release a variety of growth factors, and stimulate the
healing process (Chen, 2016).
A multitude of variables must be evaluated when designing constructs for stem
cell responses to the simulated extracellular matrix compatibility. Stimulus variables
such as oxygen values, nutrient concentrations and mechanical cues stimulate cells to
modify the secreted ECM to regulate the biological process including differentiation of
stem cells and angiogenesis for the regenerative process (Gattazzo, 2014). In the
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natural construct, the ECM serves as an adhesive support not only for cells but the
detachment of morphogens and growth factors that contribute to the maintenance of
tissue function. The engineered ECM construct must incorporate the rigor and control of
synthetic material manufacturing and favoring bioactivity to promote tissue remodeling
at various levels. The use of biomimetic regulated biodegradable materials can be
engineered using a variety of biofabricated procedures such as 3D printing in an
endeavor to mimic the biological cues of the natural ECM to incorporate the best
mechanical and degradation profile.

Extracellular Matrix-Material Interactions
The physiochemical properties of base materials, whether synthetic or natural,
must support cell viability during biofabrication, culture and degradation. The 3D
parameters of the constructs should not evoke cellular death, induce cell stress
biomarkers or alter DNA makeup to cause a negative cellular change. Many threedimensional fabricated porous constructs using single or mixed biomaterial types for in
vitro and in vivo studies for cell-construct communications and tissue integrations have
been used broadly to induce a tight cell matrix bond for tissue development. These
constructs are trying to clone the extracellular matrix and form a physical reinforcement
to allow cellular migration, adhesion, proliferation which are required for tissue
differentiation. As the progression of material science and tissue physiology continues,
the advancement of material biofabrication production to biomimic the ECM construct is
required. A precise value of porosity, cell to material surface area, safe chemical
composition and a controlled degradation rate for a stronger end result (Yannas, 1989)
are needed. For the design of an effective ECM construct platform four properties have
been laid out in the biofabrication process. First is the biodegradation rate as period of
time, second is a biocompatible chemical cocktail to reduce cytotoxicity, third is the
calculation of the microstructure taking in consideration the pore size, locations and
geometrical orientation, and fourth the overall construct size for cell migration and
angiogenesis support (Yannas,2001).
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Cell-Scaffold Interactions
The primary objective for regenerative engineering is to optimize the
biocompatibility of the 3D constructs supporting strong cell-tissue interactions. Cell-tocell biochemical communication is indispensable to instigate initial attachment, while
provoking ques for cell proliferation by the constructs surface texture and topography.
These interactions give a clear interrelationship between the surface roughness of the
biocompatible material and the tight relationship to adhesion, proliferation, and
morphology of the cells (Linez-Bataillon, 2002). Surface roughness of the biomaterial’s
mixture plays a very important role in the expression of the ECM and cell adhesion
proteins depending on the type of tissue that is being replaced by the 3D print (Grellier,
2009, Linez-Batailion, 2002). 3D biofabrication progression to finite shapes and sizes
for the ideal cell niche to promote adherence and growth has changed biomedical
device engineering. Printing constructs with high porosity and varying micrometer pore
diameters with interconnective channels to increase cell to matrix surface area for cell
attachment and tissue ingrowth are being generated. Properties of the construct being
physical, and chemical are also crucial in relation to the cell-matrix surface area
interaction. Any variation in the 3D bioprinted structure factors can have a significant
effect on cell adhesion, proliferation and differentiation in the tissue development in vitro
and in vivo.

Biofabrication Material Combinations
Ceramics, metals and polymers both natural and synthetic have been
recommended in bone tissue biofabrication (Salgado, 2004). Each material or mix of
material has many pros and cons to being the perfect implantable medical device
leading to desired shapes to mimic or having osteoinductive and osteoconductive
properties or the perfect biodegradation rate for cell and tissue survival (Peppas, 1994).
The process of biodegradability plays the greatest role in tissue regeneration if not
controlled properly tissue may reproduce but may also struggle or die due to growth
replacement rates. The period of time a biomaterial remains insoluble in the body is
crucial in characterizing the material bioactivity. Under normal physiological conditions
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the tissue must incorporate with the biofabricated construct to reinforce cell migration,
adhesion, proliferation and fully support differentiation but the biofabricated material
must biodegrade in a safe manner that will not interfere with the native tissue
remodeling development. Increasing density of the construct increases resistance to
degradation but may also be achieved with increasing the crosslink density between the
fibers (Yannas, 1989). Crosslinking has an effect on cells and used in controlling
natural and synthetic constructs. Constructs of the natural blend are derived from
sources such as fibrinogen, polysaccharides (chitosan, alginate, starch), proteins or
collagen base. Each of these biomaterials promotes and expedite cell attachment,
migration through the design, differentiation and vascularization of tissue (Salago,
2004). Over the years natural constructs have been replaced with the use of synthetic
biomaterials for bone tissue engineering (Nair,2006; Li et al., 2014).
Various types of biodegradable synthetic polymers have widely been used to
replace tissue damage at many organ levels. Poly (glycolic acid) (PGA) causes
inflammatory reactions to the surrounding tissue but has high tensile mechanical
strength and stiffness with low solubility (Yamane, 2014). Modification of poly (εcaprolactone) (PCL) allows it to be highly compatible and has been examined as a
material for controlled applications of various drug delivery models due to its low
degradation rate of 2-3 years by microorganisms. 3D printing of a composite scaffold of
PCL/hydroxyapatite (HA) with HA exposed onto the surface of scaffold for enhanced
cellular response and osteochondral engineering. (Dwivedi et al.,2020; Idris et al.,
2010). Designing for excellent compatibility and bioabsorbability for the body is Poly
(lactic acid) (PLA) as well as the PLA based copolymer poly (lactic-glycolic acid) (PLGA)
which has been approved by the FDA for clinical use. The use of a nanocomposite with
PLA has acceptable properties processing and mechanical support and as a result of its
low degradation rate. It is extensively used as a fixative device in dental applications for
bone fracture support, in medical devices for drug delivery, as well as possessing an
outstanding biocompatibility, osteoinductive and osteoconductive properties for guiding
biofabrication tissue regeneration (Zhang, 2015). PLA has four different variation’s that
are available but only poly (l-lactic acid) and poly (dl-lactic acid) have been widely
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explored as an alternative to ceramic biomaterials (Chen,2003; Zhang 2015). Poly (LLA)
has been used as resorbable suture under the product name Vicryl® and Fixsorb® an
orthopedic fixator device (Ulery, 2011). It has been suggested that copolymers such as
Poly (L-Lactide-co-caprolactone) {poly (LLA-co-CL)} copolymers are appropriate
materials for enhancing cell differentiation for bone tissue repair (Idris,2010) These
copolymers acquire acceptable mechanical properties, favorable biocompatibility and
degradability that can be used to assemble constructs and increase behavior for cellular
adhesion and proliferation (Nair, 2011).
The synthetic constructs in material science biofabrication has allowed for
designing in a variety of methods. With pore architecture being so important the
method of chemical/gas foaming came about. This technique using high pressure
carbon dioxide gas developed the method of continuous extrusion process for a high
porous structure. The saturation of the thermoplastic polymer mixes allowed designers
to have precise pore distribution and size to achieve infiltration of cells in the construct
with a suitable mechanical support (Mathieu, 2005). Leaching of particles/salts, is
solvent casting, which is a method that depends on totally on removal and complete
evaporation of the solvent utilized. This technique is a low-cost method with the
fabrication not requiring a great deal of equipment. Fabricating a multi-channel with
high interconnectivity and porosity rate is completed by the method of freeze drying.
The polymers are dissolved into a slurry and frozen then placed under very high
vacuum, so the solvent is removed yielding a fabricated construct for tissue repair
(Whang, 1995). However, each of the techniques for fabrication has some
disadvantages, such as the breakdown of the polymers using highly toxic solvents,
limitations on structure design and mechanical properties, maintain added nanoparticles
within the construct’s matrix, increased inconsistencies with pore sizes and shapes and
yielding long processing times in the lab (Bose, 2013).
To overcome these material design challenges the development of the various
3D printing methods are being used to support a higher biocompatibility and less
cytotoxicity material methodology. 3D printing allows for detailed construct design to
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support formation of blood vessels within the matrix and use geometric shapes to form
stronger mechanical supports to develop a functional replacement for bone or soft
organ tissue engineering. As the growth in regenerative medicine climbs the demand
for 3D biofabrication is expected to increase exponentially. The use of computer-aided
tissue engineering technology to customize medical devices and to procedure
constructs in a high reproducible manner with high quality control will improve the
function of tissues with high mechanical properties, increased cell adhesion for
proliferation and distribution in every surgeon’s operating room (Bose, 2013).
Biofabrication – Summarizing Trends and Strategies
With the significant progress made in all facets of biomedicine described in the
above sections, there are many different options to approach a biofabrication project
which can be successfully translated into the clinic (Gloria, 2010). Based on the
literature described above, this section summarizes the tools and the considerations
that should be taken into account by researchers and clinicians for safe and efficacious
cell-based therapies.
1) Cell based therapy by taking tissue samples from the donor after breaking down to a
cell platform and then seeding it directly to a tissue structure, supporting proliferation
and differentiation, and promoting angiogenesis.
2) A cell focus approach by using growth factor stimuli to develop a correlative
regenerated tissue
3) Design of a bioreactor as an internal or external device containing tissue. These are
linked to the body to support or replace physiological functions, and
4) Biofabricate a scaffold onto which tissue or mesenchymal stem cells are loaded and
implanted to regenerate tissue.
In order to achieve any of the above – mentioned method, the choice of the
scaffold design is of prime importance. The scaffold design should be carefully chosen
so as to allow a specific cell type to show in-growth and out- growth with the material so
to restimulate the endogenous progenitor cells and regrow the damaged area of tissue
by a cooperative action with the exogenous cells. The scaffold can be designed from
natural or synthetic material, which gives varying degradation response and temporarily
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supporting cells via cell matrix-material interactions and biochemical release. As
described in the above sections, scaffolds can be acellular or cellular. An acellular
design aids regeneration by angiogenesis, as vessels from the encompassing tissues
attach or penetrate the scaffold layout. This process allows the tissue to fill and modify
the biofabricated scaffold, which over a period of time biodegrades and allows the tissue
to sustain further growth supplied by the blood vessels. Second, is a cellular design,
where the patients stem cells, or an allogenic cell approach can be taken to seed the
biofabricated design. This method of scaffold design becomes intergraded and allows
for expansion of the engineered tissue. In order to be used in some form of tissue
engineering the biofabricated scaffolds must meet the prerequisites summarized below
(Causa, 2007; Gloria et al., 2013; Hutmacher, 2004). All the desired properties are
interdependent and hence, in many instances, it is difficult to describe them as mutually
exclusive, and hence, might result in some redundancy.

Scaffold structure and design: Regeneration of the human body is a very complex
cascade of pathways, which have a very complex coordinated event of spatial and
temporal modalities. Signal transduction is highly governed by biochemical cues which
trigger the ECM microenvironment for development (Causa, 2007). The biofabricated
structure must provide a dimensional/porous balance so as to allow for cellular
adhesion and proliferation controlling the expression of the extracellular matrix. The
extracellular matrix provides a structural and dynamic communication between cells
playing a very complex role in cellular fate, direct cell-ECM interactions, such as
migration, adhesion and remodeling influence tissue development (Alford et al, 2015).
Optimal porosity is one of the main features in the biofabricated design. Its primary
responsibility as an interconnected labyrinth is for cell-to-cell communication, adhesion,
diffusion and supportive network for vascularization as well as nutrients to cells and
tissue and removal of cellular metabolic waste (Causa, 2007). Degradation of the
biomaterial can also affect pore dimensions and could potentially change the
development of the tissue.
As a result, the design layout should provide a three-dimensional space, so to
bolster the developing tissue; support cell to cell or cell to matrix interaction while
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stimulating tissue production, whilst gaining support from vasculature. The scaffold
design should temporarily sustain tissue operations such as a load bearing support until
the new bone is formed as expected in bone regeneration.

Biocompatibility: The biomaterial choice of the biomaterial is a key feature. Natural or
synthetic material selected for biofabrication must integrate and be compatible to the
host and must have minimal to no host tissue inflammatory response. If a response
triggers an immunological cascade, the biomaterial must be non-cytotoxic, so that the
biomaterial can modulate the tissue response (Hutmacher, 2000). As a result, various
concentrations of material mixes and solvents should be tested. The testing for cell
viability or apoptotic activity represents a crucial marker in gene regulators for overall
cellular apoptosis and can be performed in vitro prior to in vivo application. In summary,
material design must support cell survival, with regulated biodegradation and resorption
rates to mimic the structural tissue extracellular matrix, and proper mechanical
properties to optimize the rate of tissue regeneration in vitro and in vivo (Butscher,
2011; Hutmacher, 2000).

Surface topography: A 3D biofabricated construct is a template for cell adhesion,
proliferation and differentiation to promote regeneration of a damaged or replaced tissue
(Salgado, 2004; Müller, 2009). Surface area for cell-matrix contact must be appropriate
to support cellular nutrients and metabolic waste. adhesion, migration and
differentiation are key factors in a cellular process and one factor that can change the
whole outcome is the substrate topography. The integration between the biofabricated
materials’ topographic patterns and cellular response can greatly improve the
functionality and long-term stability of the scaffold implant. Topography of the scaffold
can be used in a very effective manner to regulate cell adhesion migration and
differentiation (Ventre, 2012).

Degradation and restorability: Biomaterial degradation are a very complex but
important feature to consider when determining the biomaterial of choice and to be sure
it completely degrades as a tissue is reformed. Degradation rate can be tailored by the
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addition or subtraction of working groups on the material composition. It is important to
understand the discordance between degradation and regeneration times which could
lead to a problem during development. If a degradation rate is too fast this can lead to a
non-complete tissue development, while a slower degradation might result in incomplete
regeneration. Ultimately, when the biomaterial degrades it should be easily processed
and expelled without an inflammatory response within the host physiological system.

Mechanical tradeoff: Responsibility of the scaffold is to be a temporary replacement to
support the damaged tissue and all functions, especially mechanical if dealing with
osteo regeneration, while the new tissue is being regenerated. Hence, understanding
the connection between degradation of the scaffold and its mechanical properties is
imperative. Understanding that there will be a transition where the regenerative tissues
embrace a greater mechanical role as the scaffold degrades is of prime importance.

Sterilization: Another very challenging priority to scaffold properties is the requirement
of having a sterile environment guaranteed for in vivo implantation and in vitro cell work.
A crucial prerequisite to the design process is providing a sterile environment for cell
growth plate ration and avoiding contamination. To that point the biomaterial of choice,
which can be sterilized without losing its material properties, is a crucial consideration in
scaffold biofabrication.

Challenges
One of the impediments of engineering any scaffold is the ineffectiveness to
biomimic the extracellular matrix of healthy tissue in the body when multiple cell types
are integrated (Xu et al., 2013). With the ability to design a structured pattern of cells in
3D bioprinting, an optimal structure can be produced. 3D printing allows for several
advantages in regenerative medicine. Printers are adjustable and can multitask; they
can be easily reprogrammed with a new CAD template and interchangeable stainlesssteel blunt tip needles for injection to accommodate different biomaterials or cell types.
3D bioprinting is an efficient process that can reduce the waiting time of the needed
transplant organs for human or animal patients (Sachs, 2013; Xu et al., 2013) and
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hence, has a huge potential in biomedicine. 3D bioprinting could facilitate fabrication of
patient-specific tissues, and possibly formulation of complete system organs in the
future.

Conclusion
3D printing and bioprinting is versatile for tissue applications and has emerged as
a new tool for biofabrication of constructs to create well-defined intricate and
reproducible matrix architectures to replace human anatomy from disease. The use of
a 3D printed applications also allows for detailed reproducible iterations for a solid
platform for in vitro models for studying geometrical architecture on various cellular
feedback pathways, leading to enhanced mechanical production of bioengineered
constructs. With the use of CAD technology and integrations with medical software the
allows for building of custom-made iterations based on each patient-specific tissue
needs. The needed understanding of chemistry and biology for material properties,
CAD and slicers for software and the dynamics of the printer for hardware yields the
interactions for the involvement of the printing process. Therefore, choosing the correct
processing conditions and the precise material properties facilitates in the reproduction
of a high-quality 3D biofabrication. Several biodegradable polymers such as PCL,
PLGA, PLA, and PGA, and their copolymers have been used to Biofabricate 3D printed
iterations (Chen, 2013). The preference of using a synthetic polymer and their
copolymer materials is ease in processing into tissue biofabricated constructs and
extreme versatility, which allow characteristic tailoring of biocompatibility, and the ability
to vary biodegradation time, vary softness with solvents, wettability, mechanical strength
(Li, 2014). Utilization of 3D bioprinted bioinks and hydrogels for soft tissues including
skin, liver, and vasculature have been demonstrated to create in-vitro models for
bioreactor studies and drug testing applications, which is closer to reality than 3D
bioprinted tissues for organ transplantation. Over the past years, many new exciting
developments in the bioprinting field has been enabled by the development of bioinks
and hydrogels us be used in combination with polymers. Multiple new breakthroughs in
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bioink development will remain the key highlights of the future models in 3D bioprinting
for tissue engineering.
3D bioprinted constructs and bioinks/hydrogels utilized should empower three
main objectives; First, being define a space that sculpts the regenerating tissue,
Second, maintain a temporary matrix to allow for tissue functions and Third, permit a
model for tissue ingrowth support (Billiet et al., 2012). The ideal biomaterial should
mimic ECM properties and support cellular activity with interconnectivity for waste and
nutrient flow without leading to cell functional damage and to maintain mechanical
stability as biodegradation progresses to allow ECM from the cells inside the construct
to gradually replace the lost biomaterial, this highlights the development of 3D
printing/bioprinting/biofabrication for tissue engineering.
In view of the challenges and the multifactorial nature of tissue engineering and
regenerative medicine described in this chapter, it is very difficult to identify a strategy that can
go from bench to bedside. As described in the next four chapters, I have used the information
from our laboratory and the published reports to implement a bone tissue engineering strategy
which could be used in a large animal preclinical model with a long-term goal of translating it
into human medicine. This strategy consisted of generating in vitro models of human MSCs
(Chapters 2, 3), identifications of the type and the form of the polymers and nanoparticles, and
3D biofabrication of the scaffold (Chapter 4), and ultimately evaluation of the
polymer/nanoparticle/cell constructs in a rat femoral weight – bearing bone model (Chapter 5).
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Figure 1.1. Interrelation between Biofabrication, Additive Manufacturing and the Tissue
Engineering and Regenerative Medicine fields.
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Figure 1.2 Schematic Illustration of Inkjet printing on the left and pneumatic extrusion
printing on the right.
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CHAPTER II:
FUNCTIONALIZED GRAPHENE NANOPARTICLES INDUCE HUMAN
MESENCHYMAL STEM CELLS TO EXPRESS DISTINCT
EXTRACELLULAR MATRIX PROTEINS MEDIATING OSTOGENESIS
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Abstract
Purpose: The extracellular matrix (ECM) labyrinthine network secreted by
mesenchymal stem cells, provides a microenvironment to enhance cell adherence,
proliferation, viability, and differentiation. The potential of graphene-based
nanomaterials to mimic tissue –specific ECM has been recognized in designing bone
tissue engineering scaffolds. In this study, we investigated the expression of specific
ECM proteins when human fat derived adult MSCs adhered and underwent osteogenic
differentiation in presence of functionalized graphene nanoparticles.
Methods: Graphene nanoparticles with 6-10% oxygen content were prepared and
characterized by XPS, FTIR, AFM and Raman spectroscopy. Calcein-am and crystal
violet staining were performed to evaluate viability and proliferation of human fat –
derived MSCs on graphene nanoparticles. Alizarin red staining and quantitation was
used to determine the effect of graphene nanoparticles on osteogenic differentiation.
Finally, immunofluorescence assays were used to investigate the expression of ECM
proteins during cell adhesion and osteogenic differentiation.
Results: Our data shows that in presence of graphene, MSCs express specific integrin
heterodimers, and exhibit a distinct pattern of the corresponding bone - ECM proteins,
primarily fibronectin, collagen I and vitronectin. Furthermore, MSCs undergo osteogenic
differentiation spontaneously without any chemical induction, suggesting that the
physicochemical properties of graphene nanoparticles might trigger the expression of
bone-specific ECM.
Conclusion: Understanding the cell-graphene interactions resulting in an osteogenic
niche for MSCs will significantly improve the application of graphene nanoparticles in
bone repair and regeneration.
Keywords: Graphene nanoparticles; functionalized graphene, human mesenchymal
stem cells, extracellular matrix, fibronectin, collagen I, osteogenic niche

34

Introduction
Bone tissue engineering scaffolds designed to utilize cell therapies function as
delivery vehicles for osteoprogenitor cells and display their ability to attenuate the
biological function of cells capable of osteogenic differentiation. Biomimetic scaffolds
are dynamic, and their function is dependent on the interactions between the
biomaterial and the cells (Sanz-Herrera and Reina-Romo 2011). These cells can be
endogenous and be recruited from the tissues in which the scaffold is implanted, or
exogenous cells delivered to the site of injury. Cell adhesion to the scaffolds triggers
signals that can ultimately affect bone cell formation, referred to as osteogenic
differentiation.
Adult mesenchymal stem cells have emerged as a therapeutic modality in
various realms of regenerative medicine and are the preferred cells for bone-tissue
engineering. Compared to embryonic or induced pluripotent stem cells, the use of adult
MSCs avoids ethical concerns and the cells can be obtained relatively easily from a
variety of adult tissues. MSCs are typically isolated from bone marrow but can also be
isolated from whole blood, umbilical cord blood, dental pulp, skin and adipose tissue.
MSCs are spindle shaped, adherent, fibroblast-like cells that can be expanded in tissue
culture to generate primary cultures (Caplan 2007, Bieback, Kern et al. 2008). Tissue
culture expanded MSCs are a heterogenous population of cells, a subset of which have
the potential to differentiate into osteoblasts (bone forming cells), in vitro and in vivo,
when placed in an osteogenic environment. Hence, MSCs are a reliable and preferred
source of osteoprogenitors (Pittenger, Mackay et al. 1999, Dominici, Le Blanc et al.
2006).
The progression of cells into an osteogenic lineage is regulated by the differential
expression of osteoblast-associated transcription factors (Runt-related transcription
factor 2; Runx2), adhesion molecules (integrins β1/ITGB1), and extracellular matrix
(ECM) proteins (fibronectin, collagen I) (Daley, Peters et al. 2008, Frantz, Stewart et al.
2010, He, Jiang et al. 2013, Wan, Lu et al. 2013). During osteogenic differentiation, cells
initiate the synthesis of ECM, and express osteocyte-specific markers such as alkaline
phosphatase, osteopontin and osteocalcin, thus enabling the cell to progress through
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bone cell development. ECM is the non-cellular component present within all tissues
and organs, providing structural support, promoting cell migration and adhesion, and
triggering cell differentiation. ECM is tissue-specific in its composition and topology and
determines the “tissue – specific” niche. For instance, bone ECM consists of a specific
and unique organization of collagen I fibers and hydroxyapatite (Alford, Kozloff et al.
2015). Collagen I makes up more than 90% of the organic phase of bone, and the
remaining 10% consists of proteins including fibronectin, laminin and vitronectin.
Fibronectin, the major non-collagenous ECM protein, is ubiquitously expressed and
contributes to the construction and organization of the ECM, having a significant role in
cell adhesion and differentiation. Vitronectin works with fibronectin to promote cell
adhesion and proliferation at early stages of the cell–material interaction processes
(Felgueiras, Evans et al. 2015). Vinculin is a component of focal adhesions has a major
role in both the cell-to-cell and cell-to-matrix adhesion physiology. Vinculin also plays
an important role in the control of binding of actin filaments in cell adhesion to the matrix
(Bays and DeMali 2017).
Since ECM is tissue – specific, in bone tissue engineering particular attention has
recently been given to the study of bone-specific ECM (structure, topography and
biological composition). Hence, interest has shifted from inert biomaterials to constructs
that are biomimetic with the native bone ECM (Curry, Pensa et al. 2016). These
constructs can be generated either by adding MSCs (osteoprogenitors), specific growth
factors (VEGF, PDGF etc.), coating bone - specific ECM proteins such as fibronectin
and vitronectin (Mistry and Mikos 2005, Khademhosseini, Vacanti et al. 2009, Kundu,
Khatiwala et al. 2009)onto the surface of scaffolds, or by using inherently bioactive
scaffolds alone with physicochemical properties to match the native ECM. The use of
specific growth factors can be expensive and using protein coatings alone does not
result in a composition, function, microstructure, and architecture that is sufficiently
similar to native ECM. Therefore, the long-term goal of bone tissue engineering is to
develop scaffolds that can create an “osteogenic” or “bone –specific niche” for cells by
inducing the expression of bone - specific ECM proteins.
Despite the lack of knowledge on the in vivo function of MSCs, it is widely
believed that they are crucial for tissue homeostasis and regeneration in mammals
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(Nombela-Arrieta, Ritz et al. 2011). As such, MSCs are the preferred choice for use in
bone tissue engineering. When MSCs are implanted in vivo, their survival, proliferation,
differentiation and fate are dependent on the microenvironment or “niche” in which they
are placed. Cell fate is dictated not only by the ECM of the environment, but also by the
response of the MSCs to the environment. When exogenous MSCs interact with
biomimetic scaffolds, they can trigger the endogenous cells to produce ECM, or the
MSCs themselves can express ECM proteins to form the matrix (Daley, Peters et al.
2008, Frantz, Stewart et al. 2010, Assis-Ribas, Forni et al. 2018, Carvalho, Silva et al.
2019) . Thus, understanding the niche signals that are triggered, e.g., evaluating the
ECM that is generated when MSCs are implanted in a bone defect will help the
consistency and efficacy of bone tissue engineering and regenerative medicine
approaches (Gattazzo, Urciuolo et al. 2014).
Biomaterials for bone tissue engineering should be biocompatible,
biodegradable, and bioactive as determined by their ability to be osteoinductive,
osteoconductive, and be osseointegrated in vivo. Biomaterials fabricated into nanoscale
(1-100 nm) structures (nanomaterials) have been shown to mimic the native ECM and
thus, promote cell adhesion and osteogenic differentiation. Nanomaterials have been
shown to have increased bioactivity for bone regeneration compared to their micronsized counterparts and hence, warrant study as new types of biomaterials potentially
useful for bone repair (Zhang, Li et al. 2011, Grattoni, Tasciotti et al. 2012, Nosouhian,
Razavi et al. 2015). The use of nanomaterials as scaffolds has the potential to enhance
the mechanical stability, biocompatibility, and cellular survival of implanted constructs.
Graphene-based nanomaterials have recently been recognized as useful components
of bone tissue engineering scaffolds. Graphene derivatives are preferred over the
pristine form and can be produced relatively easily by functionalization of pristine
graphene, with the ultimate goal of reducing pristine graphene’s toxicity and increasing
its usability in biomedical applications (Dubey, Bentini et al. 2015, Majeed, Bourdo et al.
2017). Graphene derivatives, including nano-sheets, ribbons, and low/high/partially
oxidized graphene, graphene oxide and reduced graphene oxide have varying physical
and chemical properties and minimal to no toxicity. (Mao, Laurent et al. 2013) These
iterations can be used as components of biocompatible and biomimetic scaffolds
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specifically for bone tissue engineering (Zhang, Wang et al. 2016, Zhang, Wei et al.
2016). Therefore, despite the concerns due to toxicity, graphene-based nanomaterials
and scaffolds have been used successfully in bone tissue engineering (Dervishi, Li et al.
2009, Mahmood, Casciano et al. 2010, Nayak, Jian et al. 2010, Nayak, Andersen et al.
2011, Wang, Ruan et al. 2011, Mahmood M. 2013, Elkhenany, Amelse et al. 2015,
Jeong, Choi et al. 2016, Majeed, Bourdo et al. 2016, Bourdo, Al Faouri et al. 2017,
Elkhenany, Bourdo et al. 2017).
Our laboratory has demonstrated that a low oxygen (6-10%) functionalized form
of graphene nanocomposite (LOG – low oxygen graphene) is cytocompatible and
exhibits osteoinductive effects in vitro and osteoconductive effects in vivo when used
with fat-derived goat MSCs (Elkhenany, Amelse et al. 2015, Elkhenany, Bourdo et al.
2017). The aim of the current study was to evaluate the effect of low oxygen graphene
nanoparticles on cellular adhesion and osteogenic differentiation of human adipose
tissue derived MSCs (hMSCs), with a focus on the spatiotemporal expression profiles of
ECM proteins during these processes. Our long-term goal is to evaluate the signaling
mechanism(s) that are initiated when hMSCs are seeded on graphene nanoparticles,
and the current study is the first step in that direction. We hypothesized that the
structure and topographical features of functionalized graphene nanoparticles will create
an “osteogenic niche” for human MSCs, which will be demonstrated by an attenuation of
osteogenic differentiation and the expression and unique distribution pattern of ECM
proteins.

Methods
Isolation, ex vivo Expansion, and Characterization of Human MSCs
Stromal vascular fraction cells were obtained from human adipose tissue from
patients undergoing panniculectomies in accordance with a protocol approved by the
IRB at the University of Tennessee Medical Center, Knoxville. The hMSCs were
isolated, ex vivo expanded and characterized as described previously (Alghazali,
Newby et al. 2017). All experiments were performed using cells, from passages 2
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through 6 only, and were incubated in complete growth media (DMEM/F12, 1%
penicillin-streptomycin/amphotericin B, 10% FBS).
MSCs obtained were confirmed by their morphology, potential to undergo trilineage differentiation, and expression of specific protein markers, using methods
reported previously (Dominici, Le Blanc et al. 2006, Alghazali, Newby et al. 2017). In
vitro experiments were carried out simultaneously on control (polystyrene or plastic) and
graphitic surfaces. The control substrates were chosen as appropriate for the assays
under experimentation.
In addition to the basic characterization of hMSCs, the expression of specific
integrin heterodimers on their cell surface was evaluated in expanded cells. 1 × 106 of
hMSCs were stained with anti-human α2β1, α5β1and αVβ6 (Millipore Sigma), α9β1 and
αVβ3 (BioLegend), and αVβ5 (Developmental Studies Hybridoma Bank – University of
Iowa), and their corresponding isotype matched controls. The manufacturer’s
recommended concentrations of antibodies were used. For immunophenotyping, cells
were harvested and counted, blocked in 1% goat serum in PBS for 20 minutes at room
temperature, then stained with each primary antibody for 20 minutes at room
temperature in the dark. Subsequently, cells were washed with PBS, collected by
centrifugation and then incubated with either IgG1/APC or IgG2b/PE (Biolegend)
secondary antibodies for 20 minutes at room temperature in the dark. Finally, cells were
fixed with 4% paraformaldehyde/PBS for 10 minutes at room temperature in the dark.
Roughly 20,000 events from each staining were analyzed using a BD FACS Calibur.
The raw data was analyzed by FlowJo software.

Preparation and Characterization of Functionalized Graphene Films
Pristine graphene was modified to produce a low-oxygen functionalized form of
graphene (LOG) with 6 to 10% oxygen content as reported previously (Elkhenany,
Bourdo et al. 2017, Majeed, Bourdo et al. 2017). Briefly, graphene nanoplatelets
(Product # N002-PDR, 1-1.2nm thick, ≤10µm lateral dimensions) were purchased from
Angstron Materials (Dayton, OH) and subjected to an aqueous acidic environment (conc
H2SO4: conc HNO3: DI-water (volume ratio of 6:2:3) for oxidation.

39

For coating a surface, a 15 mg mass sample of LOG was mixed with 30 mL of
90% ethanol (200 proof, ACS reagent grade, Acros) /10%ultrapure water (18.2Mohm,
0.055uS/cm). The mixture was bath sonicated for 60 min followed by probe sonication
(Sonics Vibra-cell VCX-130 equipped with 6 mm probe tip, 100% power for 60 min in
pulses of 5sec ON, 5sec OFF). The dispersed material was then dropped using a
micropipette onto individual 15 mm plastic coverslips or in each well of a 12 well plate,
to give a coating of 0.21mg/cm2.
The physico-chemical nature of the LOG nanoparticles was confirmed by X-ray
photoelectron spectroscopy (XPS), structural analysis by Raman spectroscopy,
functional group analysis by infrared (FTIR) spectroscopy, and the surface roughness
after coating of substrates was evaluated using atomic force microscopy (AFM). XPS,
Raman, and FTIR analyses were carried out as described previously (Bourdo, Al Faouri
et al. 2017, Majeed, Bourdo et al. 2017). Briefly, XPS was performed on powder
samples placed on double-sided tape on a glass substrate, and their elemental
composition was studied using a Thermo K-alpha (Waltham, MA) XPS. IR was
performed on pressed pellets made from LOG powder sample and KBr using a Thermo
Scientific FTIR Nicolet Model 6700 Spectrometer (Waltham, MA). Raman
measurements were performed on samples of graphene powders placed on a silicon
substrate using a 514 nm laser with Horiba Jobin Yvon LabRam 800 Micro-Raman
(Edison, NJ). For AFM, the scans were obtained using tapping mode (3.90 V) at 0.5 Hz
and 256 lines, with integral gains between 0.5 and 2.5 and amplitude setpoint averaging
around 19 nm. Three different 50µm x 50µm randomly selected regions (edge, middle,
and the center) were selected. The scans were then analyzed for surface
roughness using NanoScope Analysis 1.5 (Bruker) software. Each surface scan was
analyzed with the selection command across at least two dimensions to determine
average roughness, Ra and root mean square, Rq.

In vitro Cell Viability and Proliferation on LOG Nanoparticles
Cell viability and proliferation of hMSCs on LOG was evaluated using two
independent assays over a study period of 8 days. Calcein-am fluorescence imaging,
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and crystal violet staining and quantitation were used, as described previously
(Feoktistova, Geserick et al. 2016, Austin Bow 2019).
Cell viability on LOG was assessed using calcein-am staining as per the
manufacturer’s recommendations. Briefly, 25X10 3 / cm2 hMSCs were seeded on LOG
and control substrates and were incubated with a 2µg/mL calcein-am/dimethyl sulfoxide
mix in HBSS at 370 for 5 minutes at 2, 4, 6 and 8 days post seeding. Green, fluorescent
staining was visualized and imaged using All-in-one Microscope BZ-X700 (Keyence).
Crystal violet staining and quantitation was used to determine changes in cell
mass reflecting cell viability (Feoktistova, Geserick et al. 2016). For staining, at 2-, 4-,
6- and 8-days post-seeding, cells were fixed for 10 min with 4% paraformaldehyde/PBS.
The fixed cells were stained with a 0.1% crystal violet solution in deionized water for 30
min at room temperature then washed three times with deionized water. Crystal violetstained cells were visualized and imaged using All-in-one Microscope BZ-X700
(Keyence). For quantitation, the stain was dissolved in 10% acetic acid and quantified
by measuring the absorbance at 595 nm (Synergy HT). Data was plotted and statistics
performed in Prism (Graphpad).

Osteogenic Differentiation and Mineralization
For osteogenic differentiation, hMSCs at a seeding density of 25X10 3 cells/cm2
were induced to undergo differentiation by exposing to complete growth media
supplemented with 100nM dexamethasone, 10nM β-glycerophosphate and 155µM
ascorbic acid. At 21 days, cells were fixed in 4% paraformaldehyde/PBS for 10 minutes
at room temperature and stained with alizarin red to detect calcium in the osteoblasts.
The accumulation of calcium in hMSCs was quantitated by the elution of alizarin red dye
with 10% cetylpyridium chloride and the color was read at 570 nm (Elkhenany, Amelse
et al. 2016). Background readings due to the substrates alone without any cells were
subtracted from the sample readings to eliminate nonspecific values. Data was plotted
and statistics performed in Prism (Graphpad).
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Cytoskeletal Organization and ECM Proteins
Cytoskeletal organization and MSC morphology were assessed by evaluating the
expression patterns of F-actin and vimentin using previously reported methods
(Alghazali, Newby et al. 2017). The expression of ECM proteins during cell attachment
(i.e., within 24hrs of seeding) and osteogenic differentiation (21 days after seeding) was
assessed qualitatively by immunofluorescence detection assays. A panel of ECM
proteins including, two distinct fibronectin antibodies, 181 and 182, vitronectin, collagen
I and II, laminin and vinculin were used. Briefly, hMSCs at specified time points were
fixed with 4% paraformaldehyde at room temperature for 10 minutes, permeabilized
with 0.1% Triton X-100 in HBSS at room temperature for 10 minutes, and subsequently
blocked with the Universal Blocking Reagent (BioGenex) for 30 minutes at room
temperature. Cells were incubated with 1-2ug of all primary antibodies and samples
were incubated at 4°C for 24 hours. Alexa Fluor 594 phalloidin (A12381; Invitrogen),
Vimentin (#550513; BD Pharmingen), Collagen I (#ab3470; Abcam), Collagen II
(#ab34712; Abcam), Fibronectin 181 (MAB19172; R&D Systems), Fibronectin 182
(#MAB19182; R&D Systems), Vinculin (#ab129002; Abcam), Vitronectin (#ab113700;
Abcam), and Laminin (#MAB2144; R&D Systems). The cells were washed and
incubated with appropriate Alexa Fluor – labelled secondary anti-mouse or anti-rabbit
antibodies at room temperature for 30 minutes in dark. Alexa Fluor 594 Phalloidin was
preconjugated and hence, did not require any secondary antibody treatment step. The
cells were washed twice and mounted on microscope slides with a drop of Prolong Gold
antifade reagent with 4′, 6-diamidino-2-phenylindole (DAPI; Molecular Probes by Life
Technologies). The cells were analyzed under a fluorescence microscope (Leica DMi8).
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Results
Pristine Graphene was Functionalized to Produce LOG Nanoparticles
Pristine graphene was functionalized to improve dispersibility, and a form
containing 6 to 10% oxygen was synthesized. This is referred to as low-oxygen
graphene (LOG). The LOG nanoparticles used in these experiments are distinct from
commercially available graphene oxide and reduced graphene oxide forms and have
been extensively characterized and distinguished from the other forms, as described
previously (Bourdo, Al Faouri et al. 2017, Majeed, Bourdo et al. 2017, Nima, Vang et al.
2019). The functionalized form of graphene was characterized by a variety of
physicochemical techniques. The XPS spectrum shows distinct photoemission peaks
corresponding to C1s at 284.8eV, O1s at 533eV, N1s at 405eV, S2p at 164eV, with an
average elemental composition of 88.73% carbon, 10.57% oxygen, and <0.5% of
nitrogen and sulfur (remaining from reagents used during the oxidation procedure);
thus, confirming that the synthesized form of graphene nanoparticles are indeed LOG.
Further details from the XPS spectrum demonstrate the types of functional groups
present in the samples. Both carbon (C1s) and oxygen (O1s) narrow scan spectra were
collected and analyzed. After fitting analysis, the C1s narrow scan exhibited peaks at
248.78eV (aliphatic/aromatic C), 286.14eV (C-O), 287.26eV (C=O), 288.83eV (carboxyl,
O-C=O), and 290.70 eV for −* shakeup satellite peak. For the oxygen scan (O1s), 2
main underlying peaks are present at 532.06eV for O-C and 533.69eV for O=C
(Datsyuk V 2008, Yang D 2009). This data suggests a predominantly carbon – rich
sample with hydroxyl, carbonyl, and carboxyl functional groups on the surface.
In addition to XPS, Raman and infrared spectroscopy were used to characterize
the graphene material. Raman spectroscopy provides information on the lattice
structure of the materials and is displayed in Figure1D. The main spectral features are
observed at approximately 1350 cm -1, 1600 cm-1, and 2700 cm-1 corresponding to the
D-, G-, and 2D-bands, respectively (Malard, Pimenta et al. 2009). By analyzing the
intensity of the D- and G-bands, the defect nature of the material was determined. The
nanoparticles generated in this study displayed an I D/IG ratio of 1.34, which is consistent
with other published reports from our group on this form of graphene. The FTIR spectra
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shown in Figure 1E provided evidence of oxygen functional groups, such as hydroxyl
groups by stretching mode at ~3400cm -1 and bending mode at ~1400cm-1. Carbonhydrogen and C-OH stretches are seen in the 2950–2850 cm-1 region and in the 1200–
1050 cm-1region, respectively. Carbonyl stretching mode was present at ~1720cm -1,
with sp2 stretching from the extensive hexagonal carbon framework observed at 1630
cm-1(Wojtoniszak, Chen et al. 2012). These vibrational modes observed in FTIR,
coupled with results from Raman and XPS confirm that the synthesized form of
graphene nanoparticles are indeed LOG as described previously (Bourdo, Al Faouri et
al. 2017, Majeed, Bourdo et al. 2017, Nima, Vang et al. 2019).

LOG Nanoparticles Exhibit Rough Surface
Surface roughness was evaluated using atomic force microscopy. AFM images
show that the LOG surface had mean roughness values of ~630nm Rq (or RMS, root
mean square) and ~460 nm Ra (average roughness), suggesting potential sites for cell
attachment.

Progenitor Cells are MSCs and Express Specific Integrin Heterodimers
Fibroblast morphology and tri-lineage differentiation patterns of primary cultures
generated from the human stromal vascular fraction confirm the MSC nature of cells as
described previously (Alghazali, Newby et al. 2017). Of relevance to this study, the
integrin heterodimer profile of MSCs was compared between tissue culture polystyrene
substrate and LOG surfaces. Data shows that the expression pattern is conserved on
both substrates. Specifically, there was a >90% expression of α2β1, αVβ5, α5β1 and
α5β3 heterodimers on both surfaces, suggesting that the adhesion of hMSCs on the
LOG surface is similar to that of the polystyrene surface and could be mediated via any
one or a combination of these heterodimeric integrin subunits.
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LOG Surface is Cytocompatible
Calcein – am staining and fluorescence imaging was used to confirm cell viability
as well as distribution of hMSCs on LOG surface at specific time points (Figure 2.1a).
Calcein – am is a fluorogenic, cell-permeant probe that indicates cellular health. Native
Calcein-am is non-fluorescent and shows a green fluorescence only when it reacts with
the esterase’s that are present within live, healthy cells. As a result, the green,
fluorescent signal indicates cell viability. Additionally, data shows that hMSCs were
healthy, viable and subjectively grew in population over a period of 8 days. Cells
showed a distinct pattern of adhesion and clustering on LOG surfaces relative to the
random distribution observed on tissue culture polystyrene substrate. This pattern could
be due to the clustering of cells to specific areas of LOG surfaces or that the graphene
coating in those areas is too dark to image cells. In any case, the cells that are imaged
appear healthy and hence, the LOG surface was deemed cytocompatible.
Crystal violet staining (Figure 2.1b) and quantitation (Figure 2.1c) were used to
evaluate cell proliferation. Data showed that cells adhered to LOG surface and
proliferated with time and the cell numbers were comparable with tissue culture
polystyrene substrate, further supporting the Calcein-am staining and confirming the
cytocompatibility of LOG surfaces.

LOG Nanoparticles Inherently Induce Osteogenic Differentiation
In view of the data from our previously published study (Elkhenany, Amelse et al.
2015, Elkhenany, Bourdo et al. 2017), osteogenic differentiation and mineralization of
hMSCs on LOG surfaces was assessed using Alizarin red staining and quantitation
(Figure 2.2). Data shows that hMSCs seeded on LOG nanoparticles, demonstrated
significantly greater calcium content relative to the cells on the control surface
(p=0.0018). Interestingly, this upregulation was observed in the absence of any
osteogenic inducing reagents (dexamethasone, beta-glycerophosphate or ascorbic
acid), suggesting that the LOG surface induces accumulation of calcium in MSCs
spontaneously, i.e., induces osteogenic differentiation in vitro. Calcium content was
further enhanced (p=0.0088) in hMSCs on LOG when osteogenic inducers were added
to the media. This increase was similar and as expected to that observed in hMSCs
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seeded on the control surface in the presence of the osteogenic inducers (p=0.05),
suggesting a potential synergistic effect of LOG nanoparticles and the osteogenic
inducing reagents.
In order to study the osteoinductive effect of LOG nanoparticles without any
interference from the osteogenic inducers, in vitro assays described below were carried
out in the absence of osteogenic inducers and in growth media only. Correspondingly,
to maintain the uniformity of the osteogenic status of the cells, hMSCs on the control
substrates were differentiated in the growth media supplemented with the osteogenic
inducers.

Human MSCs Display Cytoskeletal Integrity on LOG Surfaces
Cytoskeletal health and integrity of hMSCs was further confirmed on LOG
surfaces by visualizing F actin filaments using a fluorescent derivative of Phalloidin.
Fetal bovine serum in the cell media (growth and osteogenic media) is the main source
of proteins that can adsorb onto a biomaterial and stimulate production of ECM. As a
result, cytoskeletal integrity and morphology of hMSCs was evaluated in varying
concentrations of FBS, ranging from 0% - 10%. Cells were fixed 24hrs post seeding and
morphological evaluation of F-actin fluorescence showed that hMSCs on LOG in media
containing 2, 5 and 10% FBS were relatively healthy and displayed robust cytoskeletal
morphology. Cells in absence of FBS (0%) appeared rounded and unhealthy. Although
cells survived the 2, 5 and 10% FBS media on LOG surface, corresponding cells on the
control surface appeared unhealthy, were not viable and did not proliferate in media
with <10% FBS (data not shown). In order to maintain identical cell culture conditions,
hMSCs were seeded on both the control and LOG surfaces in media containing 10%
FBS in all subsequent experiments. The cytoskeletal integrity of cells was first
confirmed at 24hrs during cell adhesion e, and subsequently, during osteogenic
differentiation at day 21.
Simultaneous to the above experiments, we ensured that the stem cell nature of
hMSCs was maintained throughout the study period by evaluating the expression of
vimentin, a mesenchymal stem cell marker (Secunda, Vennila et al. 2015). Data
confirmed that hMSCs adhered to the LOG surface and expressed vimentin confirming
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that hMSCs did not lose their “stem cell” characteristics during the cell culture process
on LOG surfaces.

ECM Proteins are Expressed on LOG Surfaces
In order to evaluate the expression of ECM proteins that might be contributed by the
serum in the media, IF assays were carried out on LOG surface in the absence of cells
and only in presence of 10% FBS-containing media at 24 hours and at day 21. The
expression patterns of collagen I, collagen II, fibronectin, laminin, vinculin, and
vitronectin were evaluated. IF analyses on the LOG surface did not show the expression
of any ECM proteins in the absence of hMSCs in any of the samples tested, clearly
demonstrating that the serum proteins do not contribute to the ECM on LOG surface
and hence, do not have a role in cell adhesion or differentiation.
Next, we evaluated the expression of ECM proteins when hMSCs were seeded
on the LOG surface (Figure 2.3). The expression patterns were evaluated at 24hrs to
assess the ECM proteins involved in cell adhesion and at day 21, to evaluate proteins
involved in osteogenic differentiation. There was expression and a discrete pattern of
distribution for collagen I, fibronectin 182, vinculin and vitronectin was evident within
24hrs post-seeding. Collagen II was weakly expressed and there was no expression of
laminin, suggesting that either these proteins are not involved in adhesion and
osteogenic differentiation of hMSCs on the LOG surface, or that the specific antibodies
did not cross react. Qualitatively, the distribution patterns appeared striking and
discrete.

Discussion
In this study, we present in vitro data to show that in presence of functionalized
graphene nanoparticles with 6-10% oxygen content, human fat-derived MSCs express
and secrete a discrete and organized pattern of bone–specific ECM proteins within
24hrs post seeding. This pattern persists throughout the osteogenic differentiation
process through day 21. Noteworthy is the fact that these ECM proteins were found
only in the presence of hMSCs without any contribution from the FBS present in the
media. The cells also expressed specific integrin heterodimers, and, as judged by the
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calcium content accumulated in the cells, undergo osteogenic differentiation, suggesting
that the interaction between integrin and the corresponding ECM proteins might mediate
cell adhesion and subsequent osteogenic differentiation. Most importantly, in the
presence of LOG substrates, hMSCs undergo osteogenesis spontaneously without any
osteogenic inducers. These results prove our hypothesis that the surface chemistry and
topography of LOG nanoparticles create an osteogenic niche for hMSCs, at least in part
by inducing the expression of specific ECM proteins and thus, eliminating the need for
osteogenic inducing agents.
Graphene nanocomposites that are being developed for bone tissue engineering
are intended to serve as ECM analogs, but little is known about the mechanisms by
which they regulate cell function. It is possible that similar to gold nanoparticles,
graphene nanoparticles may interact with the ECM to up-regulate β1-integrin, generate
mechanical stress on the MSCs resulting in activation of the p38 MAPK pathway, and,
in turn, may induce spontaneous osteogenic differentiation (Yi, Liu et al. 2010, Nayak,
Andersen et al. 2011, Zhang, Lee et al. 2015). Furthermore, osteogenic inducers
included in the growth media may create an osteogenic environment for MSCs to
commit towards osteoblast lineage. The expression of specific ECM proteins by hMSCs
on LOG surfaces potentially provides cues for cells to undergo osteogenic
differentiation, the exact signaling mechanism(s) of which needs to be elucidated.
One major challenge in bone tissue engineering is to develop novel scaffolds
capable of controlling cell fate. This is the essence of biomimicry. Besides biochemical
stimuli, physical properties of scaffolds including, surface patterns, elasticity and
nanotopography have been shown to affect osteogenic differentiation of MSCs (Qian,
Gong et al. 2017, Goriainov, Hulsart-Billstrom et al. 2018, Metavarayuth,
Maturavongsadit et al. 2019). It is possible that the areas of cell clustering observed on
LOG nanoparticles overlap with areas of increased surface roughness, and hence,
provide an ideal niche for anchoring, proliferation, and potentially osteogenic
differentiation and mineralization. Published research supports that rough surfaces
allow cells to attach more easily due to the multiple sites for cell‒surface interaction and
increasing cytoskeletal stresses result in recruitment of more adhesive molecules
(Gentile, Tirinato et al. 2010, Tang, Lee et al. 2012). The results of the studies reported
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herein demonstrate that attenuation of osteogenesis may be partially due to the rough
topography of LOG nanoparticles, further supported by published studies (Deng, Liu et
al. 2015, Xu, Liu et al. 2015, Wang, Deng et al. 2016, Damiati, Eales et al. 2018, Zhang,
Lin et al. 2018, Zhang, Chen et al. 2018).
Detailed evaluation of F actin staining, and ECM protein expression profiles
showed that hMSCs adhered, spread and covered the LOG surface within 24 hours.
Distinct areas with filipodia extensions were observed, suggesting tight cell-material
interactions. Furthermore, cells arrange in multilayers, and form clusters with time,
suggesting that the LOG surface offers some cell guidance, i.e., attachment is not
random, but organized. Clustering of hMSCs, a hallmark of osteogenic differentiation
(Jackson, Bow et al. 2018) further supports the commitment towards osteoblast lineage,
which was confirmed via alizarin red staining and quantitation.

Conclusion
Our data supports our hypothesis and confirms that the LOG nanoparticles used
in these studies are cytocompatible, inductive of osteogenic differentiation and, that
hMSCs recognize graphene nanoparticles as biomimetic in vitro substrates for the
purpose of osteogenic cell culture experiments. These results are similar to that
previously reported for goat MSCs (Elkhenany, Amelse et al. 2015, Elkhenany, Bourdo
et al. 2017). We demonstrate the expression of specific ECM proteins by hMSCs in
response to a specific form of LOG graphene nanoparticles. The graphene
nanoparticles + MSC constructs provide us with a system that can be used to
understand the signaling mechanisms, or cues, that are triggered when MSCs are
committed towards the osteogenic lineage. Future experiments using this system will
potentially aid in exploring the mechanisms underlying osteogenesis mediated by the
specific ECM proteins on LOG nanoparticles, which will further improve the applicability
and the use of graphene nanoparticles in bone tissue engineering.
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Appendix
2 days

4 days

6 days

8 days

CDG2-83-2

CDG2-83-3

CDG2-83-4

CDG2-83-5

TCP

LOG

Figure 2.1 (a) Cell viability staining. Cell viability was evaluated on tissue culture polystyrene (I) and low-oxygen graphene
(LOG) (II) by calcein-am staining. Calcein-am exhibits green fluorescence and demonstrates live cells. Fluorescent
images show that human mesenchymal stem cells (hMSCs) adhered to and were viable on LOG surfaces similar to tissue
culture polystyrene at all -time points. A distinct clustering of cells was, however, observed on LOG surface as early as 2
days post seeding and continued throughout the experiment on day 8.
Scale bar =100um.
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2 days
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CDG2-83-9

CDG2-83-8

CDG2-83-7

CDG2-83-6

TCP

LOG

(b)

(c)
Figure 2.1 (b) Indirect staining (c) Crystal violet quantification. Further confirmed cell viability and proliferation when
hMSCs adhered to tissue culture polystyrene (I) and LOG(II) surfaces using crystal violet staining between days 2–8.
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Figure 2.2. Osteogenic differentiation assay. Calcium content of cells that were seeded
on tissue culture polystyrene (Control) and low-oxygen graphene (LOG) surfaces were
visualized by Alizarin red staining and subsequently quantitated. The calcium content of
cells seeded in growth media without any osteogenic inducers (undifferentiated) was
compared to cells that were exposed to differentiation media (differentiated) for 21 days.
Media blank, i.e., the tissue culture polystyrene and LOG surfaces without any cells
were used as blanks and the corresponding absorbance readings were subtracted.
Significantly different values (p<0.05) are indicated by letters. Identical letters indicate
no significance.
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A

24hrs

Collagen I

B

Fibronectin

Vinculin

Vitronectin

21 days

Figure 2.3. Expression of ECM proteins. Proteins expressed during cell adhesion
i.e., within 24hrs (A) and differentiation i.e., at day 21 (B) were assessed using IF
assays. The insets show the expression of the same proteins on tissue culture
substrate at 24hrs. Note the lack of discrete organization on the tissue culture
polystyrene surface.
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Chapter III:
VERSATILITY OF CELL RESPONSE TO GRAPHENE NANOPARTICLES
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Abstract
Mesenchymal stem cells (MSCs) can be isolated from any adult somatic tissue.
Bone marrow and adipose tissue are the two common sources. Furthermore, the
biological quality of the MSCs from both sources can vary with the donor. A
functionalized form of graphene containing 6-10% oxygen (referred to as low oxygen
graphene, LOG, by our group) is distinct from graphene oxide but shares similar
properties with the commercially available reduced graphene oxide (rGO). The effects
of LOG and rGO can be utilized as a cell-adhesion construct and/or a possible
transporter for growth factors to support osteogenic differentiation of MSCs.
Understanding the graphene-cellular interaction is essential for considering graphene
nanoparticles as a potential candidate for biofabricated applications. The
biocompatibility of LOG and rGO surfaces were assessed subjectively by cell adhesion.
Cell morphology was assessed with green fluorescent protein (GFP) transduced MSCs.
Expression of ECM proteins by human adipose stem cells and human bone marrow
mesenchymal stem cells (BMSCs) were evaluated by immunofluorescence. A panel of
specific antibodies, including vimentin, fibronectin, F-Actin, collagen I, vinculin and
vitronectin at multiple time points after seeding were used. Cell adhesion plays a crucial
part in facilitating cell fate and it is influenced by the cellular environment. This study
suggests that a surface coated with LOG or rGO or incorporated into a scaffold will be
beneficial for cell attachment, proliferation, and osteoblast differentiation/osteogenesis.
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Introduction
The extracellular matrix of tissue forms a physical microenvironment construct
where cells reside and are cued to secret factors to support the surrounding
environment. This microenvironment niche allows for a dynamic biochemical and
biophysical signaling to influence cells to complete many tasks for development, with
these cells being stem cells (Gattazzo, 2014). Stem cells express ECM molecules at
the very earliest embryonic stages of development (Zagris, 2001). The ability to identify
and isolate cells, from a variety of tissue sources from human or animal is of
extraordinary significance. Cells can be expanded boundlessly in tissue culture, and
under controlled conditions directed to differentiate into the appropriate cell type of
importance. Tissue-derived adult stem cells, such as adipose, epithelial and bone
marrow have limited potential for multi patient use due to histo-incompatibility driving a
need for a compatible therapeutic cell source.
Even though, bone marrow and adipose tissue derived MSCs exhibit similar cell
properties, their efficacy however, i.e., their biological function in vivo can vary. This is
primarily due to donor-to-donor variations. Furthermore, the cell-scaffolds’ interaction
may vary as well. In summary, the performance and efficacy of MSCs is dependent on a
multitude of factors (Figure 3.1). Mesenchymal stem cells have the ability to
differentiate into myocytes, osteocytes, chondrocytes and neurons in vitro and in vivo
(Seong, 2010). Biocompatibility of the construct is directly related in the adhesion,
proliferation rate and viability of cells (Naujoks et al., 2011). Specific physiochemical
properties of graphene-based constructs and the biocompatible is capable of aiding
stem cells proliferation and osteogenic differentiation without supplementary inducers
(Dubey, 2015).
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Methods
Adipose Tissue MSCs – Patient 3
Human adipose tissue was isolated from patients undergoing panniculectomies
in accordance with a protocol approved by the Institution Review Board at the University
of Tennessee Medical Center. After resection, the adipose tissue was transported to the
lab and immediately processed as previously described (Alghazali et al., 2017). Briefly,
the lipoaspirate was rinsed with phosphate buffered saline (PBS) and then minced into
smaller pieces for efficient digestion. Tissue was enzymatically digested in 0.1%
collagenase, 1% bovine serum albumin (BSA) and 2mM calcium chloride in PBS at
37⁰C for 30-45 mins, with intermittent shaking until a homogenous solution was
obtained. After digestion, the samples were centrifuged at 300xg for 5 minutes at room
temperature then shaken to disrupt the pellet and centrifuged a second time (Figure
3.2). The oil/fat and supernatant were removed, and the pellet of the stromal vascular
fraction (SVF) was washed with PBS. The pellet was suspended in stromal medium
(DMEM/F12, 1% penicillin-streptomycin/amphotericin B, 20% fetal bovine serum (FBS)
and passed through a 100m cell strainer to remove undigested tissue. The single cell
suspension was seeded in tissue culture flasks and incubated for 48 hours in a
humidified 5% CO2 incubator at 37⁰C. The flasks were washed with PBS to remove
loosely attached cells and fresh stromal media was added. The cells were grown to 8090% confluence and then harvested with 0.05% trypsin EDTA, for cryopreservation in
80% FBS, 10% DMEM/F12, 10% DMSO or, split and seeded into new flasks for
expansion. All experiments were performed using cells from passage 2-6 in complete
growth media (DMEM/F12, 1% penicillin-streptomycin/amphotericin B, 10% FBS).
Adipose tissue derived MSCs were characterized by flow-cytometric analysis for
expression of MSC markers and their potential to undergo tri-lineage differentiation by in
vitro adipogenesis, osteogenesis and chondrogenesis as described earlier (Dominici et
al., 2006). Differentiation was confirmed by Oil Red O staining of the lipid droplets,
Alcian blue staining of collagen, and Alizarin red staining of calcium, respectively.
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Bone Marrow MSCs
Human bone marrow mesenchymal stem cells were purchased from ATCC
(Manassas, VA USA) at passage 1. They were cultured in flasks using ATCC
recommended protocol in an incubator with humidified atmosphere, 5% CO 2, and 37oC.
Cell culture was maintained until the flask reached 85-90% confluency. Cells were then
trypsinized (trypsin 0.05%, USA) and cultured for further passages following same
protocol until passage 5. For this study passage 4 was used on all experiments. The
commercially obtained BMSCs have been demonstrated by the vendor to express the
stem cell markers and have been demonstrated to undergo in vitro trilineage
differentiation.

Alizarin Red Staining Calcium Content During Osteogenesis
Patient 3 -ADMSCs and BMSCs were cultured to 80-85% confluency in growth
media. For experimental conditions, cells were harvested and seeded at 25x103 on
LOG thin films as described in chapter 2. Cells were cultured on LOG for 21 days and
maintained in growth media without support from osteo-differentiation media. At 21-day
time points films were stained with Alizarin red.
Alizarin Red allows for visualization of calcium production which is evaluated by
staining the samples with alizarin red solution, which is a dye that binds to extracellular
calcium salts. The evaluation for calcium production was carried out comparing Patient
2 from previous study in chapter 2 to Patient 3 and bone marrow cells on graphene for
osteogenesis. The accumulation of calcium in hMSCs was quantitated by the elution of
alizarin red dye with 10% cetylpyridium chloride and the color was read at 570 nm
(Newby et al., 2020). Background readings due to the substrates alone without any
cells were subtracted from the sample readings to eliminate nonspecific values. Data
was plotted and statistics performed in Prism (Graphpad).

Green Fluorescent Protein /Red Fluorescent Protein Transduction of MSCs
Production of Lentivirus
Modification of human adipose mesenchymal stem cells were cultured in the lab
of Dr. Tom Masi. Construction and production of transduced MSCs using a functional
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population of lentiviral (LV) victors expressing enhanced red fluorescent protein (RFP)
and green fluorescent protein (GFP) were processed (Masi, unpublished). Infected
MSCs were cultured and passaged for future cell studies on biomaterials or constructs.

Cytoskeletal Organization and ECM of Patient 3 and BMSCs Proteins on LOG and rGO
Cytoskeletal organization and MSC morphology were assessed by evaluating the
expression patterns of F-actin and vimentin using previously reported methods
(Alghazali et al., 2017). The expression of ECM proteins during cell attachment (i.e.,
within 24hrs of seeding) and osteogenic differentiation (21 days after seeding) was
assessed qualitatively by immunofluorescence detection assays. A panel of ECM
proteins including, two distinct fibronectin antibodies 182, vitronectin, collagen I and II
and vinculin were used. Briefly, hMSCs at specified time points were fixed with 4%
paraformaldehyde at room temperature for 10 minutes, permeabilized with 0.1% Triton
X-100 in HBSS at room temperature for 10 minutes, and subsequently blocked with the
Universal Blocking Reagent (BioGenex) for 30 minutes at room temperature. Cells
were incubated with 1-2ug of all primary antibodies and samples were incubated at 4°C
for 24 hours. Alexa Fluor 594 phalloidin (A12381; Invitrogen), Vimentin (#550513; BD
Pharmingen), Collagen I (#ab3470; Abcam), Collagen II (#ab34712; Abcam),
Fibronectin 181 (MAB19172; R&D Systems), Fibronectin 182 (#MAB19182; R&D
Systems), Vinculin (#ab129002; Abcam) and Vitronectin (#ab113700; Abcam). The
cells were washed and incubated with appropriate Alexa Fluor – labelled secondary
anti-mouse or anti-rabbit antibodies at room temperature for 30 minutes in dark. Alexa
Fluor 594 Phalloidin was preconjugated and hence, did not require any secondary
antibody treatment step. The cells were washed twice and mounted on microscope
slides with a drop of Prolong Gold antifade reagent with 4′, 6-diamidino-2-phenylindole
(DAPI; Molecular Probes by Life Technologies). The cells were analyzed under a
fluorescence microscope (Leica DMi8).
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Preparation of Reduced Graphene Oxide Nanoparticle Thin Surfaces
Reduced graphene oxide was obtained commercially from Cheap Tubes Inc
(Grafton, VT, USA). Graphite powder yields graphite oxide when synthesized by the
Hummer’s method (Wu, 2010). The reduction by thermal methods to synthesize GO
yields rGO in achievement to minimize the number of oxygen groups attached (Pei,
2012) (Figure 3.3).
Reduced graphene oxide with a thickness of 0.7-1.2nm, Y&Y dimension at 300800nm, Purity of 99 wt.%, method by modified Hummer’s was used to generate 2D films
for this study. 4mg of rGO was mixed with 2 mL of 95% EtOH and sonicated with an
Ultrasonic unit for 1 hour keeping the water at 20-25oC. The resulting dispersion is
2mg/mL and 0.2mg/cm2 (i.e., 100l/cm2) was the desired surface amount for a 15mm
coverslip receiving 150l. Coverslips were then transferred to a vacuum oven with at
50oC and -25 psi for 1 to 1.5 hours. Coverslips were then taken for gas sterilization and
stored in the dark until needed for experiments.

Following methods were used to characterize rGO dispersions. These
characterizations were carried out at the Center for Integrative Nanotechnology
Sciences, University of Arkansas at Little Rock by Dr. Shawn Bourdo.
X-ray Photoelectron Spectroscopy (XPS) and Raman Spectroscopy on rGO
The physico-chemical nature of the rGO nanoparticles was confirmed by X-ray
photoelectron spectroscopy (XPS), structural analysis by Raman spectroscopy. XPS is
a qualitative and quantitative technique used to characterize surface chemical states for
elemental composition and binding states of the synthesized materials. An X-ray beam
excites the atoms on the surface of the sample causing a release of photoelectrons.
Synthesized rGO was prepared as films by aqueous dispersion on glass slides and
dried prior to characterization.
The synthesized constructs were analyzed via Raman spectrum. The chemical
analysis is expressed by a number of peaks, displaying the intensity and wavelength
position of the scattered light. Each of the peaks correlate to a specific molecular bond
vibration.
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Results
Patient 3 Characterization
Patient 3 MSCs were successfully isolated form adipose tissue. Flow-cytometric
analysis was used to characterize specific cell surface markers. Analysis showed that
ADSCs expressed MSC markers CD29, CD44, CD73, CD90, and CD105 in all cells and
were negative for hematopoietic markers CD34, CD45, HLA-DR and endothelial marker
CD106 expression (Figure 3.4.). Tri-lineage differentiation potential was performed for
each lineage by being supplemented by the proper induction media. Adipogenic
lineage confirmed oil droplets by staining Oil Red O, chondrogenic differentiation was
confirmed by staining with Alcian blue and osteogenic differentiation was confirmed by
Alizarin red. (Figure 3.5)

Alizarin Red in vitro Differentiation
Cells were cultured for 21 days on a graphene film coated 12 well plate. When
cultured for 21 days in presence of growth media a thin layer of mineralized tissue is
represented on the graphene film. Quantification of the alizarin red stain confirmed that
patient 3 cells performed as well as patient 2 did in pervious graphene experiments.
(Figure 3.6). Upregulation was observed in the absence of any osteogenic inducing
reagents (dexamethasone, beta-glycerophosphate or ascorbic acid), suggesting that the
LOG surface induces accumulation of calcium in MSCs spontaneously, i.e., induces
osteogenic differentiation in vitro. hBMSCs seed on LOG for 21 days expressed
significantly greater calcium content relative to the cells on the control suggesting that
the LOG surface induces accumulation of calcium in hBMSCs spontaneously without
osteogenic inducers in vitro (Figure 3.7).

Green Fluorescent Protein Transduction of MSCs
The adipose cells that were transduced were tested to see if they would be
usable in future studies. The test showed cells performed well over multiple time points
with no problems in proliferation morphology and reduction in fluorescence. Images
were taken at 24 hours and 7 days (Figure 3.8). This methodology is repeatable for
68

cells and can definitely be utilized in future studies for tracking proliferation and possible
differentiation in biofabricated constructs.

XPS and Raman Spectroscopy of rGO
XPS spectrum at 3 sample spots of rGO were investigated and the average
values showed elemental composition of 83.45%C, 12.48%O, and 4.07%N (Figures
3.9 – 3.10).
Raman of the 3 sample spots showed the ratio of intensity of D/G bands that is a
measure of the defects present on graphene the structure and particularly for
distinguishing the disorder in the crystal structures of carbon (Figure 3.11). The G band
arises from the stretching of the C–C sp2 bond in graphitic materials a result of in-plane
vibrations of carbon atoms whereas the D band is due to out of plane vibrations
attributed to the presence of structural defects and dangling sp2 carbon bonds that
break the symmetry.
Adipose tissue MSCs – Patient 3 Response to Graphene
LOG
The analysis of ECM proteins by immunofluorescence we performed in chapter 2
were repeated here using ADMSCs from patient 3 on LOG. The expression of ECM
proteins evaluated at 24 hours and 21 days by using media only on LOG as a control.
The expression patterns of collagen I, collagen II, fibronectin, vinculin, and vitronectin
were evaluated. IF analyses on the LOG surface did not show the expression of any
ECM proteins in the absence of hMSCs in any of the samples tested, clearly
demonstrating that the serum proteins do not contribute to the ECM on LOG surface
and hence, do not have a role in cell adhesion or differentiation. The evaluated
expression of ECM proteins when patient 3 MSCs were seed on LOG showed at 24
hours to assess the ECM proteins involved in cell adhesion (Figure 3.12), and, at day
21, to express proteins involved in osteogenic differentiation (Figure 3.13).
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rGO
Patient 3 ECM protein evaluated images on control and rGO. No ECM protein
expression of any ECM proteins in the absence of hMSCs in any of the samples tested,
clearly demonstrating that the serum proteins do not contribute to the ECM on rGO
surface and hence, do not have a role in cell adhesion or differentiation. Evaluation at
24 hours of ECM proteins involved in cell adhesion (Figure 3.14) were expressed and
at 21 days all ECM proteins were expressed (Figure 3.15) involved in osteogenic
differentiation, showing that rGO could be utilized as a possible construct in future
studies.
Bone Marrow Cellular Response to Graphene
LOG
Bone marrow stem cells were seeded to LOG under the same conditions and
time points 24 hours and 21 days were tested on the same ECM proteins. At the 24hour time point proteins were evaluated vimentin was positive and showed signs of
stress morphology, Fibronectin expression was evaluated but limited compared to
adipose cells, F-Actin showed microtubule formation with vinculin confirming cell
adhesion, Collagen I and vitronectin was expressed but defused. 21-day time point
showed signs of proliferation and adhesion. Vimentin showed a more defined
morphology, fibronectin was expressed but again limited as to adipose cells, F-Actin
and vinculin were expressed showing morphology and adhesion to the rGO film,
Collagen I expression was increased and vitronectin showing cell adhesion and
migration also increased (Figure 3.16).

rGO
Bone marrow cell expression showed remarkably different results on rGO. At the
24-hour time point vimentin showed bipolar morphology, fibronectin had increased
showing tight communication or aggregation of the cells. Evaluation of F-Actin showed
high cell communication and microtubule response and was confirmed by vinculin,
Collagen I expression was abundant and vitronectin confirmed adhesion. Evaluation at
21-day time point, expression of cellular behavior and morphology showed with a
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pattern described as a brush stroke in a circular formation. The patterns by each
protein expressed formed a tighter cell-cell and cell-matrix showing cell communication
and adhesion (Figure 3.17) on the rGO film.

Conclusion

We reported the comparative osteogenic capabilities of ADMSCs and BMSCs on
LOG and rGO films. The properties of graphene nanoparticles such as sizable surface
area, ability to aid in mechanical properties and utility to blend with other synthetic or
natural substrates allows for multiple material constructs to be used in cell research.
This study showed that two derivatives of graphene nanoparticles are biocompatible,
allowing for cell viability, adhesion, proliferation and support to stem cells into
osteogenic lineage identified by ECM proteins. Adipose stem cell ECM proteins
expressed immunofluorescence on both derivatives. Observation of these cells showed
increased ECM protein synthesis indicating cell-matrix adhesion to the film surface.
Observation of bone marrow stem cells on LOG showing cell morphology at both time
points became smaller and more stressed at 24 hours than 21 day which may be a
result of oxidative stress that must be further evaluated. Observations of cultured bone
marrow cells of rGO exhibited distinctly stronger capability of ECM protein expression at
24 hour and 21-day time points. Comparability of graphene nanoparticle in modified
forms blended with natural or synthetic biomaterials for biofabricated implants must be
performed to achieve the regenerative support of graphene. A in vivo animal study will
allow for the study of biodistribution of the nanoparticles and gain knowledge of a
cellular metabolic pathways that can be used to engineer future tissue biofabricated
constructs.
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Appendix

Natural

Adipose tissue
Anatomical location
Donor
Age
Gender
Underlying conditions

Potency

Source

Homing

Biomaterial/scaffolds

Bone marrow

Culture expansion

Synthetic
Site of implantation

MSCs
Dose

Safety
Efficacy

In vitro challenges

Mode of implantation

Frequency
Severity of the disease
Target

Figure 3.1. A figure to show the multitude of factors that affect the safety and efficacy of MSCs.
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Figure 3.2. Patient 3. Isolation of collected adipose-derived mesenchymal stem cells
from panniculectomies. Approved IRB protocols.
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Graphene Oxide

Reduction process by
Chemical or Thermal
methods from Graphene
Oxide yielding reduced
Graphene Oxide

Reduced Graphene Oxide
Figure 3.3. Methods for obtaining reduced Graphene Oxide. Image source from
Graphene-info.com
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CD44

CD73

CD90

CD105

CD34

CD45

CD106

HLA-DR

Counts

CD29

Fluorescence

Figure 3.4. Immunophenotyping of hMSCs by flow cytometry. Human MSCs were stained with the indicated antibodies
and then analyzed for expression by flow cytometry. MSCs all strongly express markers associated with the
mesenchymal stem cells (CD29, CD44, CD73, CD90, CD105), while expression of hematopoietic (CD34, CD45, HLA-DR)
and endothelial (CD106) markers are negative. Colored open histograms represent reactivity with the indicated
antibodies; black open histograms indicate isotype matched controls for each antibody.
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A

B

C

D

E

F

Figure 3.5. Tri-lineage differentiation assays of hMSCs. Representative images
of Alizarin Red, oil-red-o, and alcian blue stained cells demonstrating (B)
osteogenesis, (D) adipogenesis, and (F) chondrogenesis respectively, after in
vitro differentiation. A, C and F are stained, undifferentiated control cells of B, D
and F, respectively.
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Stats:
Pt. 2 Undiff vs LOG - *** (<0.0001)
Pt. 3 Undiff vs LOG - ** (0.002)
LOG Undiff Pt. 2 vs Pt. 3 – ns

Osteogenesis
Figure 3.6. Comparison of Patient 2 cells to Patient 3 cells on Graphene for
Osteogenesis. Data shows that patient 3 cells perform on graphene films the same
as patient 2. This allows for patient 3 cells to be used in future studies.
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Osteogenesis

Figure 3.7. hBMSC on Graphene. Osteogenesis by bone marrow stem cells
on a LOG surface.
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(a)
(b)
Figure 3.8. Transduction of Adipose Stem Cells. (a) 24-hour image (b) Day 7 of
tracking cells to show proliferation and retention of fluorescence.
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spot1

spot2

spot3

Name

Atomic %

Atomic %

Atomic %

average

std dev

C1s

82.54

83.61

84.2

83.45

0.69

O1s

13.16

12.48

11.79

12.48

0.56

N1s
4.29
3.91
4.01
4.07
0.16
Figure 3.9. XPS showed an approximate elemental composition of 83.45%C,
12.48%O, and 4.07%N. Summary of XPS results on rGO sample3 spots were
investigated and the averages reported for the elements of interest: C, O, and N.
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Common Acquisition Parameters Table-spot1
Parameter
Total acquisition time
Number of Scans
Source Gun Type
Spot Size
Lens Mode
Analyzer Mode
Energy Step Size
Number of Energy Steps

11 mins 20.5 secs
10
Al K Alpha
400 µm
Standard
CAE : Pass Energy 200.0 eV
1.000 eV
1361

Elemental ID and Quantification
Name
C1s
O1s
N1s

Peak BE
285.09
532.36
399.92

FWHM eV
3.05
4.02
3.70

Area (P) CPS.eV
1712876.45
660156.20
138222.48

Atomic %
82.54
13.16
4.29

Q
1
1
1

Figure 3.10. Representative data of 3 spots of rGO that were analyzed.
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Figure 3.11. Raman showed a D-band and G-band situated at approximately 1347cm -1
and 1588cm-1. When comparing the intensity of these 2 peaks it was determined they
exhibited an ID/IG ration of ~1.14.
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Vimentin

Collagen I

Fibronectin

Vitronectin

F-Actin

Vinculin

Figure 3.12. Representative image of expression of extracellular matrix proteins. Proteins of Patient 3 adipose stem cells
expressed during cell adhesion at 24 hours on Low Oxygen Graphene using immunofluorescence.
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Vimentin

Collagen I

Fibronectin

Vitronectin

F-Actin

Vinculin

Figure 3.13. Representative image of expression of extracellular matrix proteins. Proteins of Patient 3 adipose stem cells
expressed during cell adhesion at 21 days on Low Oxygen Graphene using immunofluorescence.
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Vimentin

Fibronectin

F-Actin

Collagen I

Vitronectin

Vinculin

Figure 3.14. Representative image of expression of extracellular matrix proteins. Proteins of Patient 3 adipose stem cells
expressed during cell adhesion at 24 hours on reduced Graphene Oxide using immunofluorescence.
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Vimentin

Collagen I

Fibronectin

Vitronectin

F-Actin

Vinculin

Figure 3.15. Representative image of expression of extracellular matrix proteins. Proteins of Patient 3 adipose stem cells
expressed during cell adhesion at 21 days on reduced Graphene Oxide using immunofluorescence.
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Vimentin

Collagen I

Fibronectin

Vitronectin

F-Actin

Vinculin

Figure 3.16. Representative image of expression of extracellular matrix proteins. Proteins of bone marrow stem cells
expressed during cell adhesion at 24 hours on Low Oxygen Graphene using immunofluorescence.
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Vimentin

Collagen I

Fibronectin

Vitronectin

F-Actin

Vinculin

Figure 3.17. Representative image of expression of extracellular matrix proteins. Proteins of bone marrow stem cells
expressed during cell adhesion at 21 days on Low Oxygen Graphene using immunofluorescence.
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Vimentin

Collagen I

Fibronectin

Vitronectin

F-Actin

Vinculin

Figure 3.18. Representative image of expression of extracellular matrix proteins. Proteins of bone marrow stem cells
expressed during cell adhesion at 24 hours on reduced Graphene Oxide using immunofluorescence.
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Vimentin

Collagen I

Fibronectin

Vitronectin

F-Actin

Vinculin

Figure 3.19. Representative image of expression of extracellular matrix proteins. Proteins of bone marrow stem cells
expressed during cell adhesion at 21 days on reduced Graphene Oxide using immunofluorescence.
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CHAPTER IV:
BIOFABRICATION OF NOVEL THERAPEUTICS FOR
MUSCULOSKELETAL REPAIR
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Versions of this chapter were originally presented as a Research Day Abstract as
an oral presentation for the Comparative and Experimental Medicine Department:
presented in-house only no commercial presentation:
Permission was obtained by Dr. Madhu Dhar, mentoring author of the chapter.
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Abstract
This chapter covers the core, which is Biofabrication. The long-term goal is to
develop a biocompatible scaffold containing cells and sufficient vascularization using 3D
bioprinting and bioreactor mechanics to influence the biological processes. Tissueengineering technologies have the potential to provide a more effective approach to
bone regeneration that will speed healing, improve patients’ chances of recovery from
debilitating injuries and diseases, and return normal form and function. I hypothesize
that a new nanoengineered construct composed of graphene-Poly Lactic-co-Glycolic
Acid (PLGA) will create an environment suitable for mesenchymal stem cell proliferation
and differentiation for osteogenesis and angiogenesis. I also hypothesize that in order
to improve the outcomes in the use of graphene-PLGA materials and mesenchymal
stem cells, it is important to mimic the signaling pathways that are triggered when cells
adhere to the construct and also to monitor the changes associated with these
processes for future scaffold development.
In this section, we describe the fabrication, physicochemical and biological
properties of a nanoconstruct generated for musculoskeletal repair. Scaffolds were
designed to induce human adipose tissue – derived mesenchymal stem cells
(hADMSCs) to undergo osteogenesis and angiogenesis. Scaffolds were printed using a
commercial pneumatic based Aether 1 3D printer. The printer was operated using a
numerically controlled G-code. The G-code was designed to obtain a specific hatched
lattice pattern conducive for bone cell and vascular network formation. The scaffold
consisted of a blend of two molecular weight forms of PLGAs and a low oxygen
functionalized derivative of graphene. Human ADMSCs were used to evaluate the
cytocompatibility and morphology via fluorescent assays of the nanoconstruct. A
multicomponent nanoengineered graphene-PLGA bone material could form the
foundation for novel scaffold technology to promote rapid bone regeneration to advance
bioengineering and promote human and animal health.
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Introduction
Tissue engineering using stem cell regenerative strategies with the aim to
remodel, replace or regenerate damaged tissues or organs with combining a
biodegradable scaffold in a three-dimensional matrix to form the ideal bone graft is a
significant challenge. For generations two-dimensional static cell work has dominated
the study of cellular response but a shift to a more physiological three-dimensional
format allowing for the study of biochemical markers and biomechanical stresses (Duval
et al., 2016). Biofabrication has been presented as an application of 3D manufacturing
strategies (Groll,2016). Biofabrication is defined as "the automated production of
biologically functional products with structural organization from living cells, bioactive
molecules, extracellular matrix, biomaterials, cell aggregates, through bioprinting or
bioassembly and successive tissue transformation processes" (Moroni, 2017). In
general, the biofabricated design provides a provisional 3D device to create a network
with cells and control their performance in a multiplex process in tissue development
and regeneration. No matter the tissue ECM type, a multitude of variables are essential
when designing the complexity of a scaffold for physiological tissue replacement. The
variables of importance in the design layout are architecture, mechanics,
biocompatibility and the rate of biodegradability having the surface properties for cell
adhesion, proliferation and differentiation for the biofabricated construct (Figure 4.1).
Integration of the construct into the body’s ECM allows cells to utilize unique
mechanosensitive to promote pathological progression for regeneration (Yeung et al.,
2005). The construct must also be able to stimulate biological pathways with the design
of pores, topography, growth factors, biochemical ques in vitro and in vivo to intensify
tissue viability, performance and morphogenesis (Dvir, 2011).
3D biofabricated constructs consisting of natural and synthetic polymers, with
adult MSCs presents a novel and biomimetic approach in bone tissue engineering.
Graphene has been found to be one of the most versatile biocompatible biomaterials
that can interact with physiological biomolecules for biomedical applications (Shin et al.,
2016). Currently, no studies have reported the osteogenic potential of adult MSCs
proliferating on a 3D graphene-PLGA nanoengineered construct with dynamic support
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in vivo or in vitro. Graphene nanomaterials as a scaffold has been shown to increase
cell proliferation and a positive impact on viability of human adipose-derived stem cells
(Wang et al., 2016). 3D bioprinting is the arrangement of biological and or synthetic
materials and living cells in a discrete pattern that is optimal for biomimetic bone tissue
engineering scaffolds that should be biocompatible, bioresorbable, and have the
potential to be synthesized in an implantable form. Due to the lack of microvasculature
the establishment of neovascularization is necessary if tissue engineered devices are to
be progressive and provide a physical skeleton comparable to the innate extracellular
matrix to enhance cell adherence, proliferation, and differentiation for bone
regeneration.
A nanoconstruct was biofabricated for bone engineering using additive
manufacturing with a commercial 3D bioprinter, Aether 1 (San Francisco, USA). A
consistent and reproducible pattern was biofabricated with the pneumatic based
bioprinter to print a PLGA-carbon based nanomaterial which consists in the designing of
PLGA melting protocols to determine extrusion pressures and speed values. Various
pressures were chosen based on blending viscosity and printer nozzles 0.2 mm, 0.3
mm and 0.4 mm diameters for thread runs. After an extrusion pressure was set, a grid
platform, one for each speed and nozzle, were printed and evaluated. Every test was
conducted multiple times with the results of the analysis suggested the printing
parameters used to manufacture the 0°/45°/90° deposition pattern with a diameter of 5
mm. There were 122 in total, with heights from 0.5mm to 5mm for analysis subject to
compression test, biological analysis, which consisted in cell seeding of human adipose
MSCs and viability test, to implants for a rat segmental femur study.
Poly(lactic-co-glycolic) acid (PLGA) and Graphene
PLGA
As a linear copolymer PLGA has properties to be used for biofabrication in the
areas of osteo and angiogenesis. PLGAs utilizations include drug delivery systems,
biodegradable medical suture and, of course, biofabricated scaffolds for bone and
vascular tissue regeneration. Due to PLGAs utilizations in having Food and Drug
Administration (FDA) approval for clinical use, the ability to modify surface chemistry for
biocompatibility, molecular weight and copolymer ratios to tailor biodegradation rate in
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scaffold designs is what makes PLGA the choice for the study. It is highly biodegradable
in physiological environments which is an imperative property for biomedical device
applications. PLGA can be processed at diverse ratios within its constituent monomers,
lactic acid (LA) and glycolic acid (GA) (Figure 4.2). Different ratios of LA to GA used in
polymerization can be attained and identify the copolymer by the molar ratio of the
monomers, 65:35 – 65% LA and 35% GA.
Dissolving PLGA can be performed by using a number of different solvents, such
as, chlorinated solvents, chloroform, ethyl acetate, methanol and acetone which allows
engineering the size, shape and be utilized in biomolecular transport (Makadia, 2011).
Hydrolysis of the ester linkages is the process for degradation of PLGA. During the
degradation process the byproducts lactic acid and glycolic acid are formed, but rates of
degradation have several variables involved. First, molecular weight of the polymer
giving ranges of several weeks to several months for polymer breakdown. Second, the
ratio of acids to each other plays a large step in the breakdown with a higher content of
lactic acid present making the polymer less hydrophilic, thereby absorbing less water
and consequently degrade at a slower rate. Higher amounts of glycolic acid drives the
degradation rate, the ratio 50:50 is an omission to the rule by which this copolymer
exhibits a faster degradation rate. The degradation of PLGA has given fabrication and
biofabrication a great deal of flexibility for many medical device applications.

Graphene
Graphene is a synthetic material of carbon atoms in a monolayer that is being
researched in areas from thermodynamics, biosensing and now biomaterials for tissue
engineering. Studies have shown that composite materials containing graphene and its
derivatives can promote adhesion, proliferation, and osteogenic differentiation of MSCs
in vitro (Caplan, 2005). Graphene is a 2D honeycomb high surface area lattice structure
that is can be oxidized with or without further functionalization into derivatives for
nanoengineering. Two- and three-dimensional nanocomposite materials containing
various forms of graphene, especially oxidized graphene, have been incorporated into
in vitro cell cultures to study their effect on cell proliferation and differentiation (Caplan,
2005). Commercially available derivatives of graphene include graphene oxide (GO)
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and reduced graphene oxide (rGO). GO is a form of graphene that includes the
functional oxygen also having functional groups being hydrophilic, such as carboxyl,
epoxy and hydroxyl, which allows for a higher dispersibility in aqueous solutions and
better hydrophilicity than pristine graphene (Dikin et al., 2007). The reduction of
graphene oxide by chemical treatment yields reduced graphene oxide. rGO is formed
and the oxidized functional groups are removed, to obtain a graphene material that
contains only small amounts of residual oxygen and heteroatoms.
Adding to polymers, graphene and its descendants have shown to greatly improve
mechanical properties (Sayyar et al., 2015). A modification of pristine graphene, which
result in product similar but distinct from rGO in heteroatom content, was made by the
University of Arkansas at Little Rock Center for Integrative Nanotechnology Sciences.
This modification of pristine graphene produced a low oxygen graphene with an oxygen
ratio of 6% to 10% that will be blended with PLGA and 3D printed for this study (Bourdo
et al., 2017).
The combination of the polymer PLGA with a graphene oxide has been explored
for the utilization of tissue engineering (Shin et al., 2015). Reports from several groups
including ours have shown that nanocomposites containing graphene and its derivatives
have varying physical and chemical properties, by virtue of which they can affect cell
behavior. We and other groups have shown that graphene containing nanocomposites
can promote adhesion, proliferation, and osteogenic differentiation of MSCs in vitro and
in vivo (Dubey et al., 2015; Zhang et al.,2011; Elkhenany et al., 2017; Nayak et al.,
2011), making graphene nanoparticles strong candidates for bone tissue engineering.
Various sources of stem cells, such as ESCs, MSCs, and iPSCs, have been identified
as potential osteoprogenitors for bone tissue and vascular engineering. Adult MSCs are
favored because of their multipotency, immuno-modulatory properties, and ability to
release trophic factors (VEGF). Bone marrow and adipose - derived MSCs have been
benchmarked as the most applicable cell sources for bone tissue engineering due to
their well-defined in vitro and in vivo osteogenic differentiation patterns (Al-Nbaheen et
al., 2013; Barry, 2004; Caplan, 2007; Pittenger, 2008; Storti et al., 2019). Most
importantly, the use of MSCs alleviates the need to use ES cells which is particularly
important given the ethical and the political concerns associated with ES cell use. There
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is a need to identify a cell source in the osteoprogenitors i.e., MSCs, which not only
expresses endothelial cells that produce VEGF, but also demonstrates enhanced
osteogenesis, to be efficient in both angiogenesis and osteogenesis.

Methods
All biochemicals, cell culture supplements, and disposable tissue culture supplies
were purchased from Thermo Fisher Scientific unless otherwise stated. In all
preparation steps, deionized (DI) water from a Millipore system unit with a resistance of
18M/cm was used. The molecular weights of PLGA were purchased from Sigma-Aldrich
(St. Louis, MO). The oxidized form of graphene was obtained from our collaborators at
the University of Arkansas, Little Rock. The reduced graphene oxide form of graphene
was commercially obtained (Cheap Tubes Inc).
Construct biofabrication
To fabricate a viable layered orthopedic scaffold to support sufficient osteogenesis and
vascularization. Three forms of commercially available PLGA (Sigma Aldrich):
1) 50:50 ratio and molecular weights of 30,000-60,000,
2) 65:35 ratio and molecular weight of 40,000-75,000 and
3) 75:25 ratio and molecular weight of 66,00-107,000 were used.

Functionalized form of graphene, oxidized to give graphene nanoparticles consisting of
6-10% oxygen was obtained from our collaborators (Dr. Shawn Bourdo’s group) at the
University of Arkansas at Little Rock, AR. This form of graphene is referred to as low
oxygen graphene (LOG). The synthesis and physicochemical properties of LOG
nanoparticles has been described in Chapter 3 and in published papers from our groups
(Bourdo, 2017; Elkhenany et al., 2017). 1mg powder of LOG was obtained from UALR.
Another form of functionalized graphene consisting of approximately 12% oxygen
was obtained from commercial sources from Cheap Tubes Inc (Grafton, VT, USA). This
form of graphene is referred to as reduced graphene oxide (rGO). The physicochemical
properties of rGO were provided by the manufacturer (www.cheaptubes.com). The
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specific details of rGO have been described in Chapter 3. 4.0mgs of rGO powder was
obtained.
A blend of two molecular weights of PLGA with LOG was used to 3D print the
construct (Figure 4.4-4.5). The material blend was prepared by mixing 1 gram of each
form of PLGA with 1 mL DMSO as a solvent in a 2:1 w/v ratio. 1 mg of LOG powder was
added to the PLGA blend to give a final concentration of 0.05 wt%. The mixture was
continuously rotated in a rotisserie oven for two hours at 65 oC. The mixture was hand
mixed every 15 minutes to ensure a uniform and complete blending of PLGA and
graphene. Two iterations with varying molecular weights of PLGA blended with 1.0 mg
of LOG were generated. On the second day, the mixture was gas sterilized using
hydrogen peroxide using a 28-minute protocol (Sterilis Solutions, MA). The blend was
stored in the pneumatic syringe at -20oC until use. Two iterations of the nanoconstructs
consisting of 50:65 and 50:75 molecular weights of PLGA blended with LOG were finally
fabricated.
The polymer/graphene blends were removed from the freezer and brought to
room temperature before loading the syringe onto the printer. The scaffolds were
printed on tissue culture polystyrene dish with the platform temperature maintained at
15 to 30 °C. The temperature required for extrusion depends strongly on the molecular
weights and inner diameter of the nozzle. The extrusion was conducted with 4-6 bars
pressure with an average of 0.5-1.0mm/s using a 0.2mm to 0.3mm inner diameter
nozzle. The choice of the inner diameter of the printer nozzle provides a great balance
between speed and precision. The printed scaffolds were kept at -20oC to preserve the
design. The printed scaffolds were removed from the freezer and used either in vitro or
in vivo.
Each scaffold was subjectively evaluated while printing and at completion. If visual
inspection found it unsatisfactory, the polymer blend was reheated and reprinted.

3D Bioprinter Setup
The PLGA/graphene nanoconstructs were printed using the 3D printer called
Aether 1, made by a small start-up company, Aether in San Francisco, CA. It is in the
Large Animal Regenerative Medicine Laboratory at the University of Tennessee,
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College of Veterinary Medicine (Figure 4.6). Pneumatic extrusion-based printing was
used. Unlike in FDM, where extrusion is a gear driven system, bioprinting nozzle in
Aether 1 is pressurized, therefore pressure dictates extrusion flow. Aether is an 8
pneumatic syringe extruder with a vertical retraction system with one anodized
aluminum heated syringe mount, double head FFF hot end filament extruder and
solenoid microvalve droplet jetting extruders which all move along the x-y axes, while
the anodized aluminum heated stage moves along the z axis. Printer chamber has UV
blacklight LED lighting system, automatic syringe tip cleaning areas, and center
attached camera. The printer comes with an external air compressor, which provides
air flow on a range of 2 to 100psi. The syringe units allow for nozzles of different
gauges for material selections. Heated syringe allows to print high heat polymers and
the microvalve droplet jetting allows printing of different kinds of cells in single or double
syringe loads.
The main features of Aether 1 are as follows: Extrusion System – Pneumatic
based, Print Heads – 1 Heated 30cc Pneumatic Print Head as well as 7 Pneumatic
Syringe Heads and 2 FFF Hot End Filament Extruders, Air Supply – External
Compressor, UV Crosslinking Wave Lengths - 365 nm & 405 nm, X / Y Axis - 1.055
micron [0.001055mm], Z Axis - 0.43 nanometers [0.00000043mm], Operating Pressure13.78kPa (0.13 Bars) - 689.47 kPa (6.89 Bars), Layer Resolution - 100 μm.
Biofabrication Design Parameters
CAD Software: The scaffold for biofabrication was designed using a CAD software,
Autodesk Fusion 360. The goal was to fabricate a scaffold with a pattern consisting of
alternating angles of 45o and 90o.
First, a 2D design was laid out to specify the contact angle of the scaffold. The
aim was to replicate the nozzle path on the stage. A 5mm diameter circle was formed,
and a layer-by-layer build was made to match the rat femur design. Vertical lines for
each guideline were laid out in lengths from left to right format with 0.30mm apart
making the first single scaffold layer. Once the single layer is completed, the two
construct prototypes could be made as an assembly of the design. The first layer was
secured on the grid and copied: this second layer was then relocated 0.3 mm along the
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z-axis and rotated 45°. This operation was repeated until the desired geometries were
achieved. The final pattern consisted of 15 layers for the 5mm high (Figure 4.6).
A critical point is to maintain construct porosity within the layers. The filament gap
and layer orientation of 0°/90°, 0°/45°/90° must be considered when seeding sells for
differentiation. Once the porosity values are set the strand diameter must be chosen
which is evaluated by the combination of the bars of pressure and speed, along with
your strand distance which may change as well, since its value includes the porosity
gap value for the adjustments of the strain diameter

Slicer: Once the CAD which is represented as .stl file is complete, it is then loaded in
the slicing software, Element. The scaffold design from the CAD is a series of
bidirectional cross sections, which is then processed by the slicer software, creating a
mathematical interpretation of the design. Element software provided with Aether1
bioprinter sets the slicing parameters, print dimensions, as well as the post processing
script. The slicing software effectively translates the 3D scaffold into a control language
known as a G-code file (Figure 4.7 - 4.10). Programming parameters such as print
bed temperature, stand thickness, extruder temperature, flow rate speed and pneumatic
pressure are the main parameters set manually for the bioprinting process.

Layer height design: Layer height thickness is a measure of the layer height of each
consecutive addition in the process. The layer height is crucial to the design of the
vertical resolution of the z-axis. A layer height was reviewed in two methods, 2.5mm or
a full 5mm height, one for the plain PLGA double molar ratio iteration and one for the
PLGA double molar ratio/LOG iteration based on the femur model. This is an important
consideration in the design of the constructs because we intend to use it in a weight –
bearing rat femoral defect model. Some stability issues could arise, if the strand
diameter is thin (0.2mm) and the layer height is low. It could cause the structure to
collapse.
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Physicochemical and biological testing
Instron Compression Test
After multiple prints of each iteration, analyses were conducted.

Mechanical

analysis consisted in compression on 3D PLGA 50:50+65:35+LOG and PLGA
50:50+75:25+LOG with a 5 mm diameter, 5mm height and 0°/45°/90° deposition pattern,
so to evaluate scaffolds mechanical properties. The test was conducted using an
INSTRON 5965 (Illinois Tool Works Inc, Norwood, MA), compressed until 2.5mm/min
deformation was reached (Figure 4.11).

Scanning Electron Microscopy (SEM)
SEM allows for imaging the morphology of the biofabricated construct so as to
gather data on the physical characteristics of topography, spatial distribution of the
thread spacing and porosity and analyze the variability in the materials composition. All
of these factors are fundamental to evaluate the functional biocompatibility of a
biomaterial. The constructs were prep in the lab using a SEM protocol. Samples were
place in vials. Next, a fixative solution of glutaraldehyde was poured to cover samples
at room temperature 2 hours. Samples were then washed 3 times with 0.1M of
phosphate buffer for 10 minutes each. Osmium solution prepped at 2% was then
poured over the samples for 2 hours at room temperature and kept in a dark location.
Samples were then washed 3 times with 0.1M of phosphate buffer for 10 minutes each.
Dehydration sequence was then performed by taking EtOH in increasing order of
30%/50%/70%/80%/90%/96%/100% - each percentage was for 15 minutes. Samples
were then placed in desiccator overnight then take to the scope for imaging.

Calcein Assay
Calcein-am staining was used to appraise viability cell and proliferation on the
PLGA-graphene construct. Calcein-am is a non-fluorescent compound that permeates
the cellular membrane of living cells, where intracellular esterase is immediately
hydrolyzed, a process that transforms the calcein-am to calcein identifying cell viability
on the material. 50,000 cells were seeded per sample of PLGA+graphene for 48 hours.
For evaluation, samples were incubated with 0.5 mL of staining solution, containing 10
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μg/ml calcein-am reconstituted with dimethyl sulfoxide, for 5 minutes at 37°C, and the
fluorescence was viewed on Lecia fluorescent microscope.

Biodegradation Assessment Study
Biodegradable polymers such as PLGA in a physiological environment can
degrade gradually and then dissipate following implantation. This degradation is critical
for tissue-engineering operations, on account of the polymer dissipating as functional
tissue regenerates. Interactions of cell-matrix interactions with an assortment of
biodegradable polymers have been studied (Gentile, 2014). The hydrolytic
biodegradation of PLGA may contribute an additional level of regulation over cellular
interactions: during degradation progress, the surface of the PLGA is constantly
renewed by physiological enzymatic reactions, providing a dynamic substrate for cell
attachment and growth. This focused on the degradation properties of the mixed molar
iterations of the PLGA and carbon-based nanomaterial. The iterations will be compared
in the effects of the ionic content of phosphate buffered saline (PBS) on the 3D printed
degradation properties. Therefore, in this study the direct in vitro degradation of PBS
solution with a designed continuous flow-spinner bioreactor, that can flow fluids through
the porous scaffolds in a controlled environment. The construct was systematically
inspected to reveal the variations in morphological changes and in terms of degradation
rate analyzed weight loss of the 3D printed PLGA composite construct. Then, the
different reactions can be compared to fully understand the reactions in vivo which may
be closely resembled by the degradation in in vivo. Each scaffolds iteration will be
placed into the continuous flow-spinner flask bioreactor at 37°C with 5% CO2 and
spinner at 65rpm and peristaltic pump at 55mLs per min. Initial dry weight was taken
and initial wet was taken at 48 hours in each solution. Samples weights will be
collected each week for 8 weeks for analyses and the PBS solution will be replaced
weekly. At predetermined time points, the construct pieces were removed from the PBS
solution and quickly washed with DDI water to remove excess salts or solution
accumulation on the surface. The scaffolds are air dried for one hour then weights were
measured.
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Results
In this study we chose a novel blend of two different molecular weights of PLGA
each with two different iterations of carbon – based nanoparticles to form a
nanoconstruct conducive for osteogenesis and angiogenesis of mesenchymal stem
cells. PLGA is an FDA – approved, biodegradable polymer commonly used in
biomedical research and 3D printing. The two molecular weights of PLGA were chosen
because of their distinct degradation properties (Gentile, 2014), with a long - term goal
of providing a structure to support new and damaged bone and vasculature.
The pattern design and topography of the biofabricated scaffolds has to meet the
native tissue architecture to have a strong development and achievement for a positive
cell behavior. The basement membrane of the ECM forms a multi complex mesh of
pores, fibers, ridges and contact angles (Yang, 2011). Contact guidance of cells guided
by topographical cues mimicking the ECM independent of biochemistry is the reasoning
of using PLGA and carbon-based nanomaterials for the advancement of adhesion,
migration and differentiation to promote changes in cytoskeletal organization and gene
expression. The pattern designs were fabricated to attain 75-80% porosity, between
100 and 300 µm interconnectivity, with contact angles at 45 and 90° to support the
osteogenic and angiogenic potential of mesenchymal stem cells.
The biofabricated blend and CAD design were chosen corresponding to support
the bone’s ECM architecture, which shows a polymer that is bioactive, biocompatible
and controllable biodegradability, so to support bone behavior for all the regeneration
development.

Identification of solvents on PLGA for Fabrication
There are reports to show various different solvents for PLGA polymers (Guo et
al., 2017). We first started out using an emulsion based solvent combination. The
organic solvent chloroform was used to dissolve the two molar ratios of PLGA with the
blending of the carbon-based nanomaterial. Methanol was then added to the mix to
induce a PLGA+nanomaterial precipitate. This mixture worked will but the needed
temperatures to print a construct ranged from 165 – 182oC with PSI of 85 to 100.
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Printing with 0.2mm and 0.3 mm nozzles did produce a thread. The mixing of double
molar ratios caused viscosity that was challenging to work with. The target thread size
was 200 m to 300 m diameter, for which a full height of 5 mm.
We then moved to the study using DMSO. DMSO is a polar, aprotic solvent that
is frequently utilized in biomedicine and cell culture research. This solvent can
breakdown polar and nonpolar compounds, including all molar ratios of PLGA. DMSO
plays a dual role allowing increased mobility at lower temperatures and as a polar
aprotic solvent shield’s ester bonds allowing for minimal degradation from hydrolysis
reducing biodegradation while in vitro and in vivo (Dong, et al., 2006).
We were able to accomplish a visually homogenous mixture of the two scaffolds
each with different molar ratios of PLGA with carbon-based nanomaterial and DMSO.
In our hands, DMSO was found to be suitable and hence, was used as the solvent for
the blending process. When constructs were placed in -20oC the DMSO would also be
used as a cryoprotectant.

Identification of Fabrication and Printing Conditions
General characterization consisted of the extrusion of material design with
changes in CAD or written in the G-code to evaluate material threading diameter using
different nozzle sizes, pneumatic pressure and extrusion speed values. Results from
multiple test prints using 0.2 mm and 0.3 mm nozzles at PSI test ranging from 65 to 95,
temperature ranges 45oC to 90oC and speeds 0.2 mm/s to 1.0 mm/s with heights of 15mm’s. The addition of the carbon-based nanoparticles did not alter the viscosity or
presented any print pattern issues.
The evaluation of the bioprinter’s behavior when it came to changes in
temperature variations and pneumatic pressures were applied to find the best
pressure/speed combination that will provide a diameter thread for detailed design and
porosity of the construct. After comparison of data between 0.2 mm and 0.3 mm
nozzles for thread diameter to build the construct were compared and the 0.2 mm
nozzle showed smooth clean threads with a consistent thickness. Extrusion speed of
0.6 mm/s was chosen for both material blends while the pneumatic pressure was set at
75 psi and temperatures maintained at 65°C. The highest printing quality for the Aether
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1 was obtained at the settings listed - Pressure 5-6 bar, Temperature 65oC, Extrusion
speed 0.6 mm/s and Nozzle 0.2mm.
Each construct print time was 2 hours and 14 minutes. 88 iterations of each
molar ratio were made at 0.5 mm high, and 36 iterations of each molar ratio were made
at 5 mm high dimensions. These contracts were printed to be tested in multitude of
levels from cellular culture studies, mechanical and degradation stress and in vivo study
to follow.

Compression Test
Mechanical characterization consisted of a compression test done on the Instron
unit. This test was carried out using an animator, until 50% deformation level was
reached being 2.5 mm tall. Compression test showed that the Young’s modulus of the
PLGA/carbon-based nanoparticles/DMSO scaffolds for 50:50-65:35 was 224.657 MPa
while that of 50:50-75:25 was 268.104 MPa. These values were similar for the
nanoconstructs containing LOG and rGO (Figure 4.12 – 4.13). Results showed a
PLGA/ DMSO with carbon-based nanomaterials can handle compression needed for
bone tissue engineering.

Sterilization
All iterations of PLGA and graphene mixtures were sterilized using multiple methods.
1. Steam using a 30 min cycle.
2. Gas - hydrogen peroxide gas using a 28 min cycle,
3. -20 to -80 freezer for 4h hours
4. Ultraviolet light - 2-4 hours of exposure.
Visual evaluation was first performed for each method. Subsequently, each scaffold
was tested for cytotoxicity using human mesenchymal stem cells for a seven-day
period. All samples tested with calcein AM cell viability assay. Each method of
sterilization showed they could support cell life on the material as well as proliferation.
None of the samples showed any bacterial or fungal contamination. Freezer method
was chosen for future storge and preparations of the blend. The blend was also stored
in the metal syringe at -20oC between prints with all iterations performing well. The
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constructs printed at 0.5 mm high were sterilized in -20oC freezer for several day and
then one hour of UV radiation before seeding with adult human adipose mesenchymal
stem cells. Viability of cells measured a calcein assay showing sales biocompatibility
with the construct design. To further show biocompatibility cells were seated and track
starting at 24 hours going to 21 days by images for proliferation.

In vitro Biodegradation
PLGA+graphene at 50:65 and 50:75 blend was maintained for 8 weeks in order
to determine the degradation rate on the membrane. The samples were kept at 36.8 oC
to 37.2oC with a magnetic stir bar set at 65 rpm and a peristaltic pump set at 50mL/min.
This unit ran 24 hours a day with material checks one time a week per protocol. Each
week material fatigue could be seen by eye and a weight chart was kept. Week 7 each
blend constructs microporous matrix began to show cracks that could been seen
without magnification. Crystals were found scattered on the surface of the construct
membrane. Weight loss are numbers used for the degradation index. Both constructs
showed limited weight loss that could be explained by the residual DMSO which has
been shown to reduce the degradation of PLGA by buffering of the ester bonds (Guo,
et. al., 2018) (Figure 4.14). Furthermore, it is thought that crystal formation on the PBS
may also play a role in the measurements which could skew the actual mass
degradation. Future studies using simulated body fluids will need to be performed to
have a stronger understand of PLGA biodegradation.

Scanning Electron Microscopy
The topography of the 3D biofabricated construct was assessed using SEM. As
shown in figure 4.14 (Figure 4.15 a-e), the presence of thread structure, valleys,
roughness and porosity are visible and replicated on the constructs. Figure 4 (f) was
imaged to show cell attachment on surface with extensive filopodia on the construct.
Both blends topography profile was within the limits for an optimal construct for future
studies.
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Cell Proliferation and Viability
The calcein Live/Dead fluorescent analysis was conducted to evaluate
cytocompatibility and proliferation on the PLGA+LOG construct post 48-hour seeding.
Seeding was completed throughout the construct. The evaluation and imaging of
calcein-am on the PLGA+LOG construct was present confirming proliferation and
cytocompatible on the construct, but fluorescence was weak (Figure 4.16). Leading to
the next study of seeding the constructs with transduced MSCs.

Cell Proliferation and Attachment
At multiple time points the during the culture period, the distribution of the GFP
and RFP transduced adipose MSCs were investigated on PLGA+LOG and PLGA +rGO
contracts. The visualization of the cells was imaged using a fluorescence microscope
showing PLGA+LOG using RFP cells and PLGA+rGO using GFP cells (Figure 4.17 4.20). The images show live cells on the construct at 24 hours and 7, 14, and 21 days
of the culture. Close to 100% cell viability with cells present throughout the construct
with no problems in proliferation morphology and reduction in color. This methodology
is repeatable for cells and can definitely be utilized in future studies for tracking
proliferation and possible differentiation in biofabricated constructs.

Conclusion
The advancement of additive manufacturing techniques, such as 3D
Biofabrication / Bioprinting, helps in creating 3D biocompatible implants on which
multiple cell types can be seeded. This progress in technology gives an encouraging
substitute to autogenous bone grafting and growth in material science development.
In this chapter, the architecture of a micro and nano cylindrical 0°/45°/90°
construct was biofabricated, via additive manufacturing technique, in precise 3D
bioprinting, and in conclusion analyzed. Those 3D constructs were designed of
compounded material, of 2 different molar ratios of PLGA matrix to mimic the ECM and
reinforced a carbon-based nanoparticle, which to support differentiation of cells for
osteogenesis in angiogenesis.
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This study provided data to show that we were able to successfully fabricate
PLGA/carbon nanoparticle nanoscaffolds, which exhibited adequate mechanical
strength, biodegradation, and in vitro biocompatibility. These results warrant in vivo
application in a long bone defect model to fully understand and evaluate the
biocompatibility and osteogenic potential.
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Appendix

Figure 4.1. Design layout should provide a three-dimensional space and meet as many
of the parameters as possible.
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(a.) Sigma-Aldrich
P2191-5G
P2066-5G
P1941-5G

50:50
65:35
75:25

Mol wt. 30,000 – 60,000
Mol wt. 40,000 – 75,000
Mol wt. 56,000 – 107,000

(b.)
Figure 4.2 (a). Sigma-Aldrich codes and PLGA ratios used. (b) Chemical structure of
poly (lactic-co-glycolic acid) and its monomers.
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Figure 4.4. PLGA:Carbon-based nanoparticle Mix Layout
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Figure 4.5. Layout of prints from blend mix of two molar ratios of PLGA+LOG showing a
layer print until the programmed height is complete.
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Figure 4.6. Aether 1 Bioprinter at the College of Veterinary Medicine, Large Animal
Clinical Sciences, Regenerative Medicine Lab.
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(a)

(b)

(c)

Figure 4.7. Biofabrication design – Autodesk 360 software views, (a) Front view, (b)
Side view and (c) Oblique view.
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G CODE
; Generated with MatterSlice 1.0
; filamentDiameter = 1.75
; extrusionWidth = 0.2
; firstLayerExtrusionWidth = 0.2
; layerThickness = 0.1
; firstLayerThickness = 0.1
; automatic settings before
start_gcode
G21 ; set units to millimeters
M107 ; fan off
; settings from start_gcode
G28 ; home all axes
M86 D0
M87 D1
M76 D0
M72 D0
; automatic settings after start_gcode
G90 ; use absolute coordinates
G92 E0 ; reset the expected extruder
position
M82 ; use absolute distance for
extrusion
M78 B1 P99 D0
M109 T2 S60
T0 B1
M205 X10
; Layer count: 50
; Layer Change GCode
; LAYER:0
M205 X5
M87 B1 D1
M400
M107
G0 Z1.25
G0 F4800 X147.739 Y88.189 Z1.3
; TYPE:WALL-OUTER
G0 Z0.05
M400
M87 B1 D0
M78 B1 D1
M86 B1 D1
G1 F16.5 X147.719 Y88.236
G1 X147.719 Y91.763
G1 X147.739 Y91.81
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X147.139 Y90.453
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X147.12 Y90.109
G1 X147.128 Y89.679
G1 X147.139 Y89.559
M400
M86 B1 D0
G0 F4800 X147.144 Y90.546
; TYPE:FILL
M400
M86 B1 D1

G1 F16.5 X147.12 Y90.109
G1 X147.128 Y89.679
G1 X147.139 Y89.559
M400
M86 B1 D0
G0 F4800 X147.144 Y90.546
; TYPE:FILL
M400
M86 B1 D1
G1 F16.5 X147.199 Y90.97
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X148.339 Y92.374
; TYPE:WALL-OUTER
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X148.319 Y92.347
G1 X148.319 Y87.652
G1 X148.339 Y87.625
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X148.939 Y87.303
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X148.919 Y87.318
G1 X148.919 Y92.681
G1 X148.939 Y92.696
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X149.499 Y89.137
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X149.519 Y89.113
G1 X149.519 Y87.145
G1 X149.539 Y87.139
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X150.099 Y87.104
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X150.119 Y87.105
G1 X150.119 Y89.009
G1 X150.139 Y89.013
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X150.739 Y89.339
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X150.719 Y89.292
G1 X150.719 Y87.197
G1 X150.699 Y87.187
M400

M86 B1 D0
G0 Z1.3
G0 F4800 X152.499 Y88.541
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X152.519 Y88.604
G1 X152.519 Y91.395
G1 X152.499 Y91.458
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X150.731 Y90.68
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X150.715 Y90.711
G1 X150.719 Y92.802
G1 X150.699 Y92.812
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X150.752 Y90.594
; TYPE:FILL
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X150.778 Y90.544
G1 X150.83 Y90.436
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X150.139 Y90.987
; TYPE:WALL-OUTER
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X150.119 Y90.995
G1 X150.119 Y92.894
G1 X150.099 Y92.896
M400
M86 B1 D0
G0 Z1.3
G0 F4800 X149.539 Y92.86
G0 Z0.05
M400
M86 B1 D1
G1 F16.5 X149.519 Y92.854
G1 X149.519 Y90.882
G1 X149.499 Y90.859
; Layer Change GCode
; LAYER:1

Figure 4.8. G-code that repeats for each layer. Above is 1layer of code.
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Figure 4.9. Element Slicer 3D view of 45Cylflat Nomv (3) Print time 3hours 12min
11sec.
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Figure 4.10. Display of Element model view showing Layer-Layer move of Nozzle while
printing.
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Figure 4.11. Instron compressive test on a 5mm PLGA+LOG construct.
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50-65 LOG
Specimen 1 to 1
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Load [N]

150
100
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Mean
Minimum

1

5965B13341

Load at Yield (Zero slope)
[N]
Maximum
Mean
Minimum

1

----------------Load at Total relaxation
[N]

Maximum
Mean
Minimum

1

188.20639
188.20639
188.20639
188.20639

Maximum Extension
[mm]

Maximum Load
[N]

2.50026
2.50026
2.50026
2.50026

188.19717
188.19717
188.19717
188.19717

Modulus (Automatic
Young's)
[MPa]
224.65766
224.65766
224.65766
224.65766

Load at Total creep
[N]

Extension at Total creep
[mm]

188.20639
188.20639
188.20639
188.20639

2.50026
2.50026
2.50026
2.50026

Extension at Yield (Zero
slope)
[mm]
-----------------

Maximum
Mean
Minimum

Maximum
Mean
Minimum

Extension at Total
relaxation
[mm]
2.50026
2.50026
2.50026
2.50026

Maximum
Mean
Minimum
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Figure 4.12. Young’s modulus of the PLGA/carbon-based nanomaterial/DMSO
construct for 50:50-65:35 value 224.657 MPa.
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50-75 LOG
Specimen 1 to 1
300

Specimen #
1

Automatic
ng's)
Pa]
5766
5766
5766
5766

Load [N]

200

1
0

0.0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

1.8

2.0

2.2

2.4

2.6

Extension [mm]

System ID
Maximum
Mean
Minimum

1

5965B13341

Load at Yield (Zero slope)
[N]

Total creep
m]

026
026
026
026

Specimen #

100

Maximum
Mean
Minimum

1

----------------Load at Total relaxation
[N]

Maximum
Mean
Minimum

1

213.03381
213.03381
213.03381
213.03381

Maximum Extension
[mm]

Maximum Load
[N]

2.50087
2.50087
2.50087
2.50087

210.64801
210.64801
210.64801
210.64801

Modulus (Automatic
Young's)
[MPa]
268.10427
268.10427
268.10427
268.10427

Load at Total creep
[N]

Extension at Total creep
[mm]

210.70533
210.70533
210.70533
210.70533

2.50087
2.50087
2.50087
2.50087

Extension at Yield (Zero
slope)
[mm]
----------------Extension at Total
relaxation
[mm]
0.25896
0.25896
0.25896
0.25896

Page 1 of 1

Figure 4.13. Young’s modulus of the PLGA/carbon-based nanomaterial/DMSO
constructs for 50:50-75:25 higher value at 268.104 MPa.
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(a)

PLGA+LOG Biodegradation
140
120

133.1

130.3

130.47

132.44

81.16

81.04

83.38

124.16

125

125.1 124.57

82.12

84.1

81.55 85.84

113.34

WEIGHT (MG)

100
80

80.12

83.03

50-65

60

50-75

40
20
0
Initial

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Week 7

Week 8

(b)
(c)
Figure 4.14 (a)Both constructs showed limited weight loss that could be explained by
the crystal formation on the PLGA by the PBS. (b)PLGA+LOG at start. (c)at 8-week time
point of degradation in dynamic bioreactor.

127

a.

d.

50:65 PLGA+LOG

50:75 PLGA+LOG

b.

e.

50:65 PLGA+LOG

50:75 PLGA+LOG

c.

50:65 PLGA+LOG

f.

50:65 PLGA+LOG+hADMSC’s

Figure 4.15. SEM images of microarchitecture of blended PLGA with LOG. (a - c)
50:65 PLGA+LOG. (d - e) 50:75 PLGA+LOG and (f) 50:65 PLGA+LOG+hADMSCs.
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(a)
(b)
Figure 4.16. Cell viability and adhesion on PLGA+LOG construct using calcein-am
analyzed 24 hours post seeding at 5x. (a) Top view with pore (b) Side view.
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a.

b.

c.

d.

Figure 4.17. PLGA+LOG utilizing RFP cells to track proliferation at (a) 50:50/65:35 at
24 hours. (b) 50:50/65:35 at 7 days (c) 50:50/65:35 at 14 days and (d) 50:50/65:35 at 21
days.
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a.

b.

c.

d.

Figure 4.18. PLGA+LOG utilizing RFP cells to track proliferation at (a) 50:50/75:25 at
24 hours. (b) 50:50/75:25 at 7 days (c) 50:50/75:25 at 14 days and (d) 50:50/75:25 at 21
days.
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a.

b.

c.

d.

Figure 4.19. PLGA+rGO utilizing GFP cells to track proliferation at (a) 50:50/65:35 at
24 hours. (b) 50:50/65:35 at 7 days (c) 50:50/65:35 at 14 days and (d) 50:50/65:35 at 21
days.
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a.

b.

c.

d.

Figure 4.20. PLGA+rGO utilizing GFP cells to track proliferation at (a) 50:50/75:25 at 24
hours. (b) 50:50/75:25 at 7 days (c) 50:50/75:25 at 14 days and (d) 50:50/75:25 at 21
days.
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CHAPTER V:
IN VIVO MODEL TO EVALUATE OSTEOINDUCTION,
OSTEOCONDUCTION AND OSSEOINTERGRATION OF
BIOFABRICATED NANOSCAFFOLDS
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Abstract
Surgeon’s face some of the most challenging bone deficiencies. Reconstruction
is limited to patient autografts or some biomedical device implant to facilitate bone
regeneration. Bone tissue engineering focuses on therapeutic concepts to by using the
applications of cellular biology, chemistry of material science and biomedical
engineering by utilizing small animal model for translation. Therefore, this section of the
study is to investigate multiple rat models using a novel 3D biofabricated PLGA and
carbon-based nanoparticle construct in an intramuscular implant model and a
reproducible 5mm critically sized mechanical load bearing segmental femur defect
model. An analysis of the results including radiological, immunohistochemical staining
and microcomputed tomography to give insight to future studies.
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Introduction
The examination of the biological mechanism was described in 1959 with
experiments in spinal fusion treatment by Hurley et al called the “Guided Bone
Regeneration” (GBR) (Hurley et al., 1959). The understanding of GBR is the
development of a mechanical barrier that is transplanted to the site to prolong cells
migrating to the site such as fibroblast from surrounding tissue that will impede bone
development. In hopes that favored cells such as osteogenic and pluripotent cells from
the bony tissue or periosteum promote growth in the defect (Liu, 2014).
The regenerative process in the body for bone tissues experiences the same
healing demeanor as other tissue wounds. First step following the initial damage to the
tissue is hemostasis. Platelet activation along with vascular eruption are seen at the
site. Immediately growth and clotting factors are supporting the coagulation cascade as
the platelets pack the vasculature to form a stable clot of fibrin (Thiruvoth, 2015). The
recruitment of cells stimulating multiple signaling cascades in response to the
inflammation process such as polymorphonuclear (PMN) cells and later macrophages
are import to debris removal (Wang, 2006). The continued stimulation of a great many
factors in the immune process continues as the end result is proliferation of new
supported tissue. The process of healing the bone matrix is complex hoping the end
result of the biofabricated construct stimulates recruitment and differentiation of MSCs
to the osteoblast lineage and the local osteoblast further stimulates the extracellular
matrix for new bone formation. The 3D biofabricated nanoconstruct must try to meet
the grafting gold standard for bone healing and repair. Will the construct stimulate
differentiation of endogenous or transplanted cell lines to formation being
osteoinductive? Is the construct osteoconductive by providing a 3D frame for uniformity
and growth on the surface. Osseointegration is the balanced anchorage of a construct
accomplished by direct bone-to-construct contact. The model of a critical sized
segmental defect is the most important approach of taking a biocompatible biofabricated
construct from bench to bedside for regenerative medicine.
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Bone: Complex Structure
Highly dynamic, complex nanocomposite architecture and intricate cellular
composition is the makeup of the structure bone. Bone physiology is an understanding
that is crucial for tissue engineers to take a biofabricated construct from bench to
surgical setting. The composition of this organ has components that are organic and
inorganic leading to its complexity. Type I Collagen and water is the organic phase
allowing viscoelasticity and rigidity, while hydroxyapatite matrix makes up the complex
stiffness and structural reinforcement composing the inorganic component and noncollagenous proteins responding from cellular behavior forming a microenvironment
(Webster, 2007). This complexity is based on a system structural architecture forming
at diverse levels including cortical and cancellous bone at the macroarchitecture,
osteons and Harversian system at micro, lamellae at sub-micro, minerals and fibrillar
collagen at the nanoarchitecture and finishing at the sub-nano with collagen, minerals
and non-collagenous proteins (McAllister, 2007). Trabecular bone containing increased
porosity is at the distal and proximal ends surrounded by a layer of cortical bone to
progress the transfer of the articular load (Webster, 2007). This transfer in the load
stimulus in a healthy bone has been described in many studies using Wolff’s law (Frost,
1994). Biofabrication must also understand the complex porosity within the bone
structure. With a porosity range of 50-90% of its average 1mm spacing for trabecular
bone and 3-12% for cortical bone makes a complex geometrical structure remodeling
challenging (Barrère et al. 2008).
The structure further broken-down into layers at a microscopic range
shows that mineralized collagen fibers stacked in layers in a parallel form called lamella
are approximately 3-7 micrometers and staked in a +/- 45o forming the trabecular struts.
Replicating the lamella in bone engineering is very important as their formation contains
the Haversian canal which contains the blood vessels and nerve for bone support and
nutrition (Rho, 1998). The dynamic properties of bone are controlled by a very
intertwined activity of cells: osteoblast – bone forming, osteoclast – bone consumer and
osteocytes- bone remodeling mechanosensors, that reside in the intramedullary canal
within the bone marrow (Marks, 2002). Bone is continuously remodeling tissue based
on very demanding functional and structural mechanical loading requirements. Porosity
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and mineralization make up the composition and the cortical and trabecular orientations
and architecture describes the mechanical properties. From a biofabrication
geometrical analysis of the bone matrix a material design needs to be a composite
material that supports the lamellar matrix design, influences cell behavior, biodegrades
the same as the remodeling activity and further stimulates the mechanical properties of
bone.
Experimental model – Critical size defect
With the advances in biofabrication focusing on multiple forms of engineering to
optimize organ growth two important needs that must be maintained and considered,
first the biocompatible biomaterial and second the animal defect model, to calculate
outcomes and effectiveness of the construct. When establishing model design, you
must develop a standardized process in evaluating the needed tissue growth of study,
which is osteogenesis for our team. The model must have a “critical size defect” (CSD)
which was defined by JP Schmitz stating that the animal of the study must have the
smallest diameter intraosseous damage in the appropriate bone that will not regenerate
spontaneously during the lifetime of the model (Schmitz, 1986).

Femur segmental defect
To determine if the biofabricated construct complies with the qualifications of
biocompatibility and mechanical strength, the construct must be accountable to testing
in vitro and in vivo. A segmental long bone defect in order to be a critical size is
configured by multiplying 2.0-2.5 by the diaphyseal diameter (Garcia-Gareta, 2015).
From a researcher’s perspective and communication with both human and animal
orthopedic surgeons that long bone segmental trauma are the most demanding graft
sites to repair to support load bearing issues. The implant to the graft site being natural
or synthetic most undergo physiological stress soon after implant, in defiance of the
surgeon’s approach in which internal fixation support, but also experiences lack of
vascular coverage to support bone regeneration and tissue repair. The content and
structural design must intel mechanical properties to take load bearing stress as well as
maintain all the levels of structure- nano, micro, and macro for cell support and growth.
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The mechanical characteristics of the biofabricated construct must complement the
bone graft surroundings not allowing for structural failure which is imperative to allow
advancement of tissue repair. The engineered external construct must support sensory
transduction to support mechanical signals to stimulate surrounding progenitor cells into
differentiation of the desired new tissue (Tzioupis, 2007). With the 5mm critical size
defect being reproduced successfully and by implanting our PLGA-LOG construct we
are now investigating the potential for osteogenesis.

Osteoinductive Study of PLGA+LOG Biofabricated Construct
An osteoinduction study is an important process in the biofabrication of a
possible bone construct. This process is defined in which osteogenesis occurs by the
implantation of a biomaterial in the pocket of connective tissue with the result of new
bone formation. Chai et al. 2012 states that osteoinduction has many factors that must
be met by the biomaterial (Chai et al 2012). Properties should include surface
topography including all levels architectural geometry, composition solubility effect of
the biomaterial, inflammatory response that stimulates chemotaxis of osteoclast to the
biomaterial, and the implantation site and healing time of the animal model (Li et al.,
2011, Chai et al., 2012). The biofabricated biomaterial should activate bone formation
heterotopically, implying the enlistment of immature cells and the stimulation of these
cells to expand into precursors of mature bone cells to support the impute of the
biomaterial’s properties are osteoinductive and not stimulated by osteoconductive
formation by the implantation (Davies, 2000). Analyses of osteoinduction helps to
understand the mechanism of bone healing in the presence of the construct when used
in vivo.
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Methods
Construct Biofabrication – For Intramuscular and Femur Study
Intramuscular and femur constructs were biofabricated from double molar ratio
PLGA+LOG using additive manufacturing with the Aether 1 bioprinter as previously
described in chapter 4. Construct outer and height dimensions remained. On day of
surgery acellular constructs were removed from -20oC freezer and placed under UV
irradiation for 1 hour before implant. Cellular constructs were removed from -20oC
freezer and placed under UV irradiation for 1 hour then seeded with 1x10 6 hADMSCs
and incubated overnight. Constructs were brought to operating room one at a time as
needed for implant.

In-vivo Intramuscular Study
Surgical Procedure
All animal handling and surgical procedures were strictly conducted under the University
of Tennessee Institutional Animal Care and Use Committee (IACUC).

Each group consisted of 6 Sprague-Dawley rats 8-12 weeks old and weighing
between 225 and 240g a muscle implantation of a biofabricated construct to evaluate
the osteoinductive capacity of a construct in bone healing. Evaluation of osteoinductive
potential of a novel construct will provide valuable information on the mechanism by
which the progenitor cells undergo differentiation. Each patient will be anesthetized with
isoflurane at 1.5 to 2% with 2 L/min Oxygen by induction tank then placed on mask
support for remaining time in the operating room. Before surgery, each rat will be given
the analgesic buprenorphine (0.05 mg/kg) based on IACUC protocol. Next, removal of
hair from the hindquarter, using small clippers. The skin area was then prepped for
sterility with chlorhexidine and alcohol. While holding the skin taught, using a sterile
blade, make a longitudinal incision of about 10-12 mm, and the entire femoral shaft will
be exposed using blunt dissection. Using thumb forceps to hold the edge of the skin
and slowly separating the skin from the muscle using Metzenbaum scissors. Using the
blunt dissection, a 4-5 mm deep pocket was made in the biceps femoris. The acellular
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or cellular construct was carefully inserted into the muscle pocket. Suturing the fascia
overlying the muscle was done using 4-0 PDS resorbable suture. Closure of skin
incision was completed with 4-0 suture. For the 3 days postoperative, the rats will be
given buprenorphine injection every eight to twelve hours for pain management and
antibiotic will be in the Gatorade water mix and changed every three days. Each group
was assessed at a 14-day time point.

In-vivo Femur Study
Surgical Procedure
All animal handling and surgical procedures were strictly conducted under the University
of Tennessee Institutional Animal Care and Use Committee (IACUC).

Each group consisted of 6 Sprague-Dawley rats 8-12 weeks old and weighing
between 225 and 240g. A defect of critical size in the rat femur - measuring 5 mm of the
hind limb of each rat was performed in a rotating format (Figure 5.1) will be used to
evaluate the osteogenesis and angiogenesis of production by the scaffold. Each patient
will be anesthetized with isoflurane at 1.5 to 2% with 2 L/min Oxygen by induction tank
then placed on mask support for remaining time in the operating room. Once removed
from the tank the patient was placed in a lateral position with procedure side up. Before
surgery, each rat will be given the analgesic buprenorphine (0.05 mg/kg) based on
IACUC protocol. Next, removal of hair from the hindquarter, using small clippers. The
skin area was then prepped for sterility with chlorhexidine and alcohol. While holding the
skin taught, using a sterile blade, make a longitudinal incision of about 12-15 mm, and
the entire femoral shaft will be exposed using blunt dissection. The fascia will be cut
separating the tensor fascia lata and biceps femoris muscles, and the vastus lateralis
muscle will be freed from the greater trochanter to the lateral femoral condyle. 2 cuts
(one proximal and the other distal) in the middle of the diaphysis will be made, and a
5mm bone segment will be cut and removed using a reciprocal saw. The defect will be
held in place using a 1.1 mm K-wire, which will be placed in the intramedullary cavity
between the proximal and the distal ends of the defect. The K-wire is a thin, semi-stiff
wire used in orthopedic surgery to assist in holding structured bone in place, and the
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small diameter allows for its use in the rat model as a form of intramedullary nailing. The
K-wire will be inserted into the 3D PLGA: Carbon-based nanoparticle biofabricated
construct and then held at the proximal and distal locations. Suture the fascia overlying
the muscle using 3.0-5.0 PDS resorbable sutures and close the wound.
For the 7 days postoperative, the rats will be given buprenorphine injection every eight
to twelve hours for pain management and antibiotic will be in the Gatorade water mix
and changed every three days.
Constructs receiving cells were placed in 10mm petri dish, then seeded with one million
hADMSCs then placed in the incubator at 37oC 12-16 hours before surgery. This step
will ensure that the cells impregnate the construct.
Groups were formed for the study.
Group 1 - PLGA 50:50/65:35+1.0mg Low Oxygen Graphene
Group 2 - PLGA 50:50/75:25+1.0mg Low Oxygen Graphene
Group 3 - PLGA 50:50/65:35+1.0mg Low Oxygen Graphene with human adiposederived mesenchymal stem cells
Group 4 - PLGA 50:50/65:35+1.0mg Low Oxygen Graphene with human adiposederived mesenchymal stem cells
Each group will be assessed at 60-day time point. Rats from each treatment group will
be euthanized at specified time point and bone healing will be evaluated with
conventional radiological analysis, microcomputed tomography, histomorphometrically
using H&E and von Kossa staining for use in the histological visualization of calcium
deposits.

Radiology analysis – Femur Study
A digital radiography system (Philips Easy Diagnost RF System; Cannon DR
plates (CXDI-50G); EDR6 Clinical Diagnostic Radiography System) was used to assess
bone healing. X-rays of the patients were taken 12 hours post-surgery to confirm correct
K-wire and construct placement as well as to establish a base line for the study. A
series of X-ray analysis in a lateral plane were conducted at 12 hours, 7 days, 30 days
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and 60 days post-surgery to assess formation of newly formed mineralized bone tissue
and changes within the segmental bridging.
Microcomputed Tomography Imaging – Femur Study
Micro-CT analysis is to provide data on the temporal progression of
mineralization development during the regenerative process of the femur. Preparation
for micro-CT imaging, all femurs were stored in 10% formalin for 48 hours, then placed
in cotton wrap soaked in 70% ethanol and stored in a 50mL conical tube for shipping.
Femur specimens were sent to Roseman University of Health, College of Dental
Medicine. Specimens were then processed using a desktop Micro-CT system (SkyScan
1173, Bruketr Kontich, Belgium) to perform the evaluations. The unit is equipped with a
sample tube and aluminum filter, femurs were scanned at an energy of 80 kVp and
intensity of 100 μA, resulting in a pixel size 31.99 μm and 1120 rows x 1120 columns.
Each femur was placed in a cylinder and attached to holder with the femur oriented
perpendicular to the image plane.
3D data analysis of the full femur was evaluated. The region of interest (ROI)
was completed manually by drawing polygonal regions. The analyzed ROI included the
defect region and adjacent newly formed bone. Analyses included tissue area, bone
area, percent bone area / tissue area (bone volume density), trabecular thickness (Tb.
Th), trabecular separation (Tb. Sp), trabecular number (Tb. N) and total porosity (Po
total). Threshold values range of 45-65, 65-85, 85-105 and 105-255 were selected for
segmentation of the PLGA/carbon-based nanoparticle construct and newly formed
bone. 3D models were generated in CTAn and formed in a. stl format for visual
representation.

Histological and Immunohistochemistry Staining
Intramuscular tissue surrounding the implant and femoral tissue from the critical
size defect were prepared for histological examination. Samples were sent to the
appropriate labs for prep and cuts. Extra slides were requested for in-house
immunostaining. Masson trichrome was to analyze surrounding connective tissue.
ECM marker Fibronectin was used to analyze cell-matrix communication. CD34 and
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von Willebrand Factor was used to analyze vessel density. CD44 analyzed MSC
recruitment to the construct site.

Intramuscular Study
Samples were sent to the Ridge Microtome Services where samples were
embedded in paraffin. Hematoxylin and eosin (H&E) and Masson's trichrome staining
was performed on deparaffinized sections to evaluate histological features with extra
slides cut for inhouse IHC to be performed for osteogenic and endothelial markers. For
immunohistochemistry, Day 1 - paraffin sections were deparaffinized with xylene 2
times for 20 minutes each and rehydrated with serial concentrations of ethanol gradient
starting with 100%, then 95% then 70% at 5 minutes each all at room temperature.
Subsequently, sections were rinsed in distilled water for 5 minutes.
Antigen retrieval steps: First, place samples Target Retrieval Solution (DAKO,
Carpinteria, CA) at 80-85oC for 30 minutes; then, remove container with slides from
water bath in DAKO solution allow to cool at room temperature for 20 minutes, then
decant solution with PBS at room temperature for 5 minutes.
Primary antibody staining: Surround the samples on the slide with ImmEdge pen
(Vector Laboratories, Burlingame, CA), next add 1% Triton X-100 in PBS solution into
the circled area for 30 minutes at room temperature followed by PBS wash for 5
minutes. Incubate sample in Super Block (ScyTek Laboratories, Logan, UT) at room
temperature for 30 minutes. Next add Primary Antibody Solution (Dilution in Super
Block) at 200 L volume (In-house List Below); In house sections were incubated with
the primarty antibody in humidified chambers at 4°C overnight.
Ridge Microtome Services:
1- Hematoxylin and eosin
2- Masson’s trichrome
In-house Primary IHC:
1- Fibronectin (1:100, abcam ab23751)
2- Osteopontin (OPN) (1:100 abcam ab8448)
3- Cluster of differentiation 44 (CD44) (1:200 abcam ab157107)
4- Von Willebrand Factor (vWF) (1:200 LS-BIO LS-B9918)
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5- Cluster of differentiation 31 (CD31) (1:200 LS-BIO LS-B12093)
6- Cluster of differentiation 34 (CD34) (1:100 abcam ab185732)
7- Sp7/Osterix (1:100 abcam ab22552)
Day 2 – Remove primary antibody solution with a 1% PBS-TWEEN 20 wash for 5
minutes. Next, add Peroxidase Blocking Solution at room temp for 10 minutes followed
by wash with PBS-TWEEN 20. Next, add Goat anti-Rabbit IgG Biotinylated at 4 drops
to each sample for 30 minutes room temp. Rinse with PBS-TWEEN 20 3 times
carefully. Now add Streptavidin Peroxidase (Vector Laboratories) at 4 drops to each
sample at room temp for 30 minutes. Rinse with 1x Tris Buffered Saline 3 times
carefully. In separate beaker mix NovaRed Substrate Kit Peroxidase: 5mL of DI water,3
drops Reagent 1, 2 drops Reagent 2, 2 drops Reagent 3, 2 drops Hydrogen Peroxide –
add 200 L of mix to each sample for 15 minutes. Rinse with PBS-TWEEN 20 2 times.
Day 2 - Phase III – Rinse slides with tap water, then immerse in Hematoxylin
stain (Vector Laboratories) at room temp for 5 minutes, rinse with tap water until clear
water is coming off sample. Next Acid Rinse – Slides were then put into a glass holder
and at a medium motion slides were moved up then down (dip) repeating 10 times
(Motion may cause sample to lift off slide – watch carefully), then same motion in tap
water 10 dips, move over to Bluing Solution for 5 dips, followed by tap water with 15
dips. Next, dehydrate slide in an ethanol gradient with 95% for 3 minutes then up to
100% for 3 minutes, last move slide to xylene 2 times at 5 min each then lay slides to
side for mounting.
Mounting will be done with Limonene-mount (Electron Microscopy Sciences, Hatfield,
PA) apply 2 drops then gently add 22x22x1mm coverslip – limiting bubbles to the
sample viewing area or moving coverslip once applied. Lay flat to dry overnight.

Femur Study
Samples were randomly divided into two groups of 12. First twelve were sent to
Ridge Microtome Services where samples were decalcified and the remaining twelve
were sent to Ratliff Histology Consultants, LLC and prepped in calcified IHC cuts.
Decalcified femurs were done with Hematoxylin and eosin (H&E) and Masson's
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trichrome staining with 7 extra slides cut for inhouse IHC staining. Staining was
performed with primary antibodies specific to osteogenic and endothelial markers.
Same protocol followed from intramuscular study and ICH markers for decalcified femur
samples.
Ridge Microtome Services:
1- Hematoxylin and eosin
2- Masson’s trichrome
In-house Primary IHC:
1- Fibronectin (1:100, abcam ab23751)
2- Osteopontin (1:100 abcam ab8448)
3- Cluster of differentiation 44 (CD44) (1:200 abcam ab157107)
4- Von Willebrand Factor (1:200 LS-BIO LS-B9918)
5- Cluster of differentiation 31 (CD31) (1:200 LS-BIO LS-B12093)
6- Cluster of differentiation 34 (CD34) (1:100 abcam ab185732)
7- Sp7/Osterix (1:100 abcam ab22552)
Ratliff Histology Consultants, LLC - Calcified sample stains:
1- Von Kossa/MacNeal’s stain
2- Masson-Goldner trichrome

Results
Surgical Postoperative – Intramuscular Study
All 6 rats underwent the surgical procedure well. All construct implants stayed within
the muscle pouch and no discharge or swelling during the 14-day length of the study.
All rats had a positive weight gain.
Surgical Postoperative – Femur Study
All 24 rats underwent the surgical procedure well. All construct implants having the hole
3D printed made allowed for a successful manipulation of the K-wire. Postoperative
recovery was successful without any complications in all the rats. Postoperative
management was without any negative issues. There was no postoperative medical
146

complications or infections throughout the sixty-day study. All rats in both studies
remained in good health during the experimental duration, with no signs of stress or hair
loss and positive gaining of weight in the sixty-day period following surgery.
Radiographic results – Femur study only
Rats underwent protocol sedation at 24 hours, 7 days, 30 days and 60 days for tracking
of implant and changes in bone structure. Correct positioning in a lateral recumbent
position of the limb containing the implant 24 hours post-surgery to check K wire
position or any possible complications.
7 days post-surgery changes in bone formation both distal and proximal of the
construct in both acellular and cellular constructs. All rats were mobile still showing no
signs of complications or depression. Palpation of the limb was done showing complete
mobility of the knee and hip regions.
One-month post-surgery a notice of some movement of the K-wire has taken
place. Various changes in bone structure on both sides of the construct implant. Some
outcropping or finger like projections showing signs of early stages of bone remodeling
were beginning to show radio-opaque on the radiographs as well as changes in the
medullary cavity. Palpation of the limb showed no signs of mobility issues or swelling of
tissue or redness to the sight and each rat was weight bearing and gaining weight.
Two months post-surgery, formation of new bone was observed in several rats
and in both acellular and cellular groups but a higher bridging on bone and less
remodeling in the medullary cavity in groups containing the 50:65 PLGA+ LOG.
(Figures 5.2-5.9 shows representative comparisons for each iteration (a) Phantom
(b) radiological view at 24 hours and 60-day end point (c) stl of each threshold of
micro-CT).

Micro-CT
The unbiased technique is measuring bone at multiple densities. Multi-level
thresholding is to evaluate bone mass at multiple density levels to reduce the difference
of cortical bone from trabecular bone. Femur analysis by micro-CT confirmed results in
regard to the construct involvement and the amount of new bone formation. All 24
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femur defects in both acellular and cellular groups showed some bony formation after
60 days. Femurs with PLGA 50:65 acellular and cellular showed the highest values of
newly formed bone. 3D stl reconstructions confirmed percent bone area / tissue area
(bone volume density) showing a difference in both acellular and cellular groups. The
evaluating results for the complete threshold of 45 to 255 showed no significant change
throughout the bone development of the construct (Figure 5.10). Next, I decided to
evaluate possible bone development at each threshold by utilizing the percent bone
area / tissue area and plotting against the intact phantom femur. The stl images
represents as an increase in threshold levels indicating formation of less dense bone to
calcified cartilage to new bone modeling (Freeman, 2009). These results showed that
PLGA+LOG 50:65 had a higher performance than PLGA+LOG 50:75 (Figure 5.11)

Immunohistochemistry and Histology
Histological analyses were performed on all 6 Intramuscular and 24 femurs. Routine
staining by Masson’s Trichrome and Hematoxylin-Eosin for all sets.

Intramuscular Immunohistochemistry
Samples of PLGA-LOG were removed from the muscle pouch site. The study
had an n=3 acellular and n=3 cellular using human adipose stem cell source.
Observation of the H&E staining tissue-construct interface showed no signs of
inflammatory response or bacterial infection. Samples in both sets showed positive
markers showing the cell communication with the biofabricated construct matrix.
Cellular samples of CD 34 and vWF identified increased vascular frequency around the
implant. Marker CD 44 showed MSC recruitment potential by the construct.
Osteogenic marker OPN suggested in the dark brown dense tissue around the
construct indicated osteogenic response. These results indicate the PLGA+LOG
construct contains all properties for an osteoinductive material. (Figure 5.12 -5.13)

Femur Immunohistochemistry
Confirming the visual of radiological and micro-CT analysis, IHC confirmed that
formation of bone tissue in the defect area and construct for all four groups. von Kossa
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stain was used to visualize new bone formation with, and counter stained with
MacNeal’s tetrachrome for unmineralized tissue. Calcified embedded sections showed
amounts of von Kossa - mineralized tissue (black) within the defects and constructs
(Figures 5.14 – 5.17). In the cellular group’s greater amounts of mineralization and
bridging were formed. In figure 5.18 the statistical analysis of the von Kossa shows the
50:65 LOG had a higher performance in the acellular construct and the 50:75 LOG
construct was supported by the hADMSCs during the in vivo study. Mesenchymal stem
cells acquire the possibility of differentiating into osteoblast if environment ques are
present or aid to the native osteoblast which is supported by Miro CT and
histochemistry. The extracellular matrix protein fibronectin confirms cell to matrix
communication and support by the construct in both acellular and cellular samples.
Bone formation in both PLGA groups by endochondral ossification based on the amount
cartilage templates formed and over period of development replaced by bone matrix
(Figures 5.19 – 5.22) to confirm increased bone remodeling and bone formation, we
performed immunostaining of OPN marker which expressed an enhanced response.
Cellular marker CD44 confirmed MSC migration throughout the multilayer construct.
Cell markers CD34 and vWF expression confirmed and angiogenic response by the
construct.
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Conclusion

Double molar ratio blend PLGA plus LOG are novel alloplastic biofabricated
constructs that will support bone enhancement procedures. Within the limits of the
study, osteogenesis was partially enhanced using the two different iterations in acellular
and cellular when implanted into a critical sized rat femur defect. Although numerous
innovations over the last decades, this bone construct offers an equally dynamic
combination of osteoconductive three-dimensional structure, osteogenic cells and
osteoinductive growth factors with encouraging mechanical properties and could
support and stimulate vascularization. The micro-CT and histology results of the study
showed the iterations supported increased bone volume and under surgical conditions
mechanical properties needed for a biofabricated implant. Future growth on this study
using the segmental femur defect over longer time points and various concentrations of
graphene nanoparticles will hopefully allow for optimization to bone formations and
stronger support to our PLGA-LOG biofabricated construct.
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Appendix

Figure 5.1. Overview of Femur Surgical Construct Implant.
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Figure 5.2. Overview of results Femur 1 50:65 PLGA-LOG Acellular – Decalcified. (a) shows phantom femur micro-CT scan
with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 1 Femur 50:65 acellular and 60-day post X-ray. (c) (1)
micro-CT femur 1 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3) Threshold 6585, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.3. Overview of results Femur 4 50:65 PLGA-LOG Acellular – Calcified. (a) shows phantom femur micro-CT scan
with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 4 Femur 50:65 acellular and 60-day post X-ray. (c)
micro-CT femur 4 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3) Threshold
65-85, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.4. Overview of results Femur 7 50:75 PLGA-LOG Acellular – Decalcified. (a) shows phantom femur micro-CT
scan with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 7 Femur 50:75 acellular and 60-day post X-ray.
(c) micro-CT femur 7 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3)
Threshold 65-85, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.5. Overview of results Femur 11 50:75 PLGA-LOG Acellular – Calcified. (a) shows phantom femur micro-CT
scan with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 11 Femur 50:75 acellular and 60-day post X-ray.
(c) micro-CT femur 11 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3)
Threshold 65-85, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.6. Overview of results Femur 15 50:65 PLGA-LOG Cellular – Decalcified. (a) shows phantom femur micro-CT
scan with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 15 Femur 50:65 cellular and 60-day post X-ray.
(c) micro-CT femur 15 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3)
Threshold 65-85, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.7. Overview of results Femur 19 50:65 PLGA-LOG Cellular – Calcified. (a) shows phantom femur micro-CT scan
with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 19 Femur 50:65 cellular and 60-day post X-ray. (c)
micro-CT femur 19 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3) Threshold
65-85, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.8. Overview of results Femur 20 50:75 PLGA-LOG Cellular – Calcified. (a) shows phantom femur micro-CT scan
with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 20 Femur 50:75 cellular and 60-day post X-ray. (c)
micro-CT femur 20 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3) Threshold
65-85, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.9. Overview of results Femur 22 50:75 PLGA-LOG cellular – Decalcified. (a) shows phantom femur micro-CT
scan with stl of ROI slices equal to all samples. (b) 24-hour X-ray of Rat 22 Femur 50:75 cellular and 60-day post X-ray.
(c) micro-CT femur 22 with stl views of bone growth around the PLGA-LOG construct – (c2) Threshold 45-65, (c3)
Threshold 65-85, (c4) Threshold 85-105 and (c5) Threshold 105-255.
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Figure 5.10. Results for the complete threshold of 45 to 255 showed no significant change throughout the bone
development of the construct.
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Figure 5.11. Results showing bone development at each threshold by utilizing the percent bone area / tissue area and
plotting against the intact phantom femur.

163

Masson’s Trichrome
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CD 34

Figure 5.12. Representative image of the Intramuscular Osteoinductive Study Acellular Sample. Red arrows identify
areas of antibody expression at the tissue-construct interface.
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Figure 5.13. Representative image of the Intramuscular Osteoinductive Study Cellular Sample. Red arrows identify
areas of antibody expression at the tissue-construct interface.
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Von Kossa MacNeal

Goldner’s Masson Trichrome

Figure 5.14. Representative image of Femur 4 Region of Interest 50:65 PLGA-LOG Acellular. Representation of
Calcified cuts stained with von Kossa MacNeal- mineralized bone expressed with black color and Goldner’s Masson
Trichrome- collagen expressed with green color. Brown scale bar: 2000µm.
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Von Kossa MacNeal

Goldner’s Masson Trichrome

Figure 5.15. Representative image of Femur 11 Region of Interest 50:75 PLGA-LOG Acellular. Representation of
Calcified cuts stained von Kossa MacNeal- mineralized bone expressed with black color and Goldner’s Masson
Trichrome- collagen expressed with green color. Brown scale bar: 2000µm.
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Von Kossa MacNeal

Goldner’s Masson Trichrome

Figure 5.16. Representative Image of Femur 19 Region of Interest 50:65 PLGA-LOG Cellular. Representation of
Calcified cuts stained von Kossa MacNeal- mineralized bone expressed with black color and Goldner’s Masson
Trichrome- collagen expressed with green color. Brown scale bar: 2000µm.
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Von Kossa MacNeal

Goldner’s Masson Trichrome

Figure 5.17. Representative Image of Femur 20 Region of Interest 50:75 PLGA-LOG Cellular. Representation of
Calcified cuts stained von Kossa MacNeal- mineralized bone expressed with black color and Goldner’s Masson
Trichrome- collagen expressed with green color. Brown scale bar: 2000µm.
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von Kossa Analysis
50:65 Acellular vs Cellular

Cellular 50:65 vs Cellular 50:75
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5.18. von Kossa analysis of acellular vs cellular constructs. Data shows that 50:75 LOG performs with cellular
support and 50:65 LOG performs without cellular support in vivo.
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Figure 5.19. Representative Image of Femur 1 Region of Interest 50:65 PLGA-LOG Acellular. Representation of
Decalcified cuts stained with Masson’s Trichrome, Immunohistochemical staining for ECM protein - Fibronectin, Osteo
marker - Osteopontin, Cell Markers CD44 and CD 34 with windows identifying expression of stain. Brown scale bar:
2000µm.
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Figure 5.20. Representative Image of Femur 7 Region of Interest 50:75 PLGA-LOG Acellular. Representation of
Decalcified cuts stained with Masson’s Trichrome, Immunohistochemical staining for ECM protein - Fibronectin, Osteo
marker -Osteopontin, Cell Markers CD44 and CD 34 with windows identifying expression of stain. Brown scale bar:
2000µm.
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Figure 5.21. Representative Image of Femur 15 Region of Interest 50:65 PLGA-LOG Cellular. Representation of
Decalcified cuts stained with Masson’s Trichrome, Immunohistochemical staining for ECM protein - Fibronectin, Osteo
marker - Osteopontin, Cell Markers CD44 and CD 34 with windows identifying expression of stain. Brown scale bar:
2000µm.
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Figure 5.22. Representative Image of Femur 22 Region of Interest 50:75 PLGA-LOG Cellular. Representation of
Decalcified cuts stained with Masson’s Trichrome, Immunohistochemical staining for ECM protein - Fibronectin, Osteo
marker -Osteopontin, Cell Markers CD44 and CD 34 with windows identifying expression of stain. Brown scale bar:
2000µm.
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CHAPTER VI:
CONCLUSIONS AND FUTURE DIRECTION
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CONCLUSIONS AND FUTURE DEVELOPMENTS
This thesis presents a characterization of the relationship of MSCs
working with graphene nanoparticles, then forming a blended PLGA-graphene
cylindrical construct using the additive manufacturing technique 3D bioprinting for
biofabrication in bone tissue engineering.

The material design for the 3D

constructs utilizing a PLGA matrix, which provides cellular support for ECM
production during the organic phase, reinforced with LOG nanoparticles, which
supports the ECM transfer of cells in the mineral phase of the regenerative
development.
The first part of the design was showing that undifferentiated MSCs would
support a relationship and longevity on 2D films of LOG. The important
component consisted of the blending and characterization of the PLGA-LOG for
printing on the Aether1 bioprinter. The use of DMSO changed the approach at
many levels using two molar ratios of PLGA and a nanoparticle. Characterization
consisted in fiber width, using various conical nozzles and a continuous pressure
and speed settings. Those results were used to establish a printing protocol to
meet all parameters to find the best pressure and speed combination that could
provide a fiber at 0.2mm diameter.
As the construct building blocks came together, samples were printed at
0.5mm high and 5mm in diameter and were sterilized in multiple methods to
check material stability. Cell viability was measured with Calcein-AM and
showed positive results which allowed to move to seeding constructs with
transduced MSCs for biocompatibility, proliferation and migrations up to the 21day time point. The results showed that the blend using DMSO did not have a
negative effect on long term cell patterns. The final study was implanting the
5mm x 5mm construct into a 5mm critical sized segmental femur defect to show
in vivo compatibility. This work opened the door to many questions and many
directions for future work.
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3D bioprinting has encountered accelerated progress over the last five years.
Future developments of the research deal with material, construct and biological
aspects.

Material development: Various combinations of single ratios and multimaterial
printing outside this study and various concentrations of LOG and rGO need to
be studied. This could increase mechanical and biological enhancement and
optimize topological ques for cellular ECM enrichment.

Construct developments: Multimaterial extrusion allows for biofabricating
complex architecture with rapid and smooth transition between divergent
biomaterials. Porosity is very important to the whole process which depends on
fiber distance and layer and angle orientation. If any variance in those
parameters, porosity dimensions and geometrical output will vary as well allowing
for analysis of various cell lines. Construct geometry can impact mechanical
behavior.

Biological developments: Multiple methodologies can be used to proceed in
biological investigations. Further studies on various stem cell lines and coculturing would greatly support the construct’s ability to be studied for an ECM
matrix for multiple organs. Bioprinting 3D tissue models for simulation of a
disease environment for clinical studies could be utilized. This will allow for open
access to the 4D bioprinting of dynamic tissues with designs in programmable
constructs for dynamic variations from biological triggers.
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